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Abstract 
 
Chronic inflammation is intimately linked with cancer development and 
progression and therefore reducing or eliminating inflammation represents a 
logical treatment and prevention strategy. Studies have shown that anti-
inflammatory agents have anti-tumour effects in cancers, with reduced 
metastases and mortality.  Current use of anti-inflammatory agents in the 
treatment and prevention of cancer is limited by their toxicity and side effects. 
The emerging field of nanotechnology allows the fundamental properties of a 
drug to be altered, creating a product with improved reactivity and 
bioavailability, leading to more targeted treatments and reduced dosage. In the 
present study, the genotoxic effects of three commonly used anti-inflammatory 
drugs; aspirin, ibuprofen and hydrocortisone, in their bulk and nano forms were 
evaluated on peripheral blood lymphocytes of healthy donors using the comet 
assay and the micronucleus assay. In order to determine any anti-cancer 
effects, these agents were also tested in peripheral blood lymphocytes in 
patients with haematological cancers. The glucocorticoid hydrocortisone was 
also evaluated for anti-oxidant capacity. Our results demonstrate that the nano 
versions of each drug produced a different response than the bulk counterpart, 
indicating that a reduction in particle size had an impact on the reactivity of the 
drug. Our results also indicate that the nano versions of each drug were less 
genotoxic than the bulk formulation, further emphasising the potential of 
nanoparticles as an improvement to current treatment options. We also found 
an anti-oxidant effect with hydrocortisone, with a more profound effect seen with 
the nano formulation.  
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1 Introduction 
Cancer is one of the largest public health concerns with more than 331 000 
people diagnosed in the UK in 2011 and an estimated 1 in 3 people in the UK 
will develop cancer during their lifetime (Cancer Research UK, 2014). Studies 
have revealed that the health and economic burden of cancer in the European 
Union to be  €126 billion per year (Luengo-Fernandez et al., 2013). With a 
worldwide estimate of 8.2 million cancer deaths in 2012, the need to find cost-
effective preventative and treatment measures is vital. The emerging field of 
nanotechnology has created a new dynamic in medicine and pharmaceutical 
production with many intrinsic properties of substances being amplified at the 
nanoscale. This widens the scope for existing pharmaceutical agents currently 
being used in cancer treatment as their effects may be enhanced with a 
reduction in particle size. Promising results have already been obtained using 
non-steroidal anti-inflammatory drug (NSAID) nano particles (NPs) when 
compared to the bulk substance for the treatment and prevention of cancer 
(Najafzadeh et al., 2016). In this study, the comet and micronucleus assays 
were used to determine the genotoxic effect of aspirin nano-suspensions (Asp 
N) and ibuprofen nano-suspensions (Ibu N) when compared to bulk 
suspensions in peripheral blood lymphocytes of healthy individuals and patients 
with respiratory diseases. Results showed a decrease in DNA damage, of both 
healthy individuals and those with disease states, when treated with Asp N and 
Ibu N when compared to the bulk suspensions. A decrease in DNA damage of 
lymphocytes treated with Asp N when compared to untreated lymphocytes from 
healthy individuals was also noted. Although these results are promising for NP 
treatment, other studies suggest an increase in toxicity with a decrease in 
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particle size. Osman et al. (2010) assessed the toxicity of zinc oxide and 
titanium dioxide NPs revealing an increase in DNA damage with increasing NP 
concentrations. The enhanced ability of NPs to cross lipid membranes could 
result in a shift in their toxicity, and therefore it is necessary to evaluate the 
effect of NPs on target cells. Previous work in our laboratory has examined at 
NP formulations in peripheral blood lymphocytes (PBL) from patients with 
various types of cancer including lung, prostate and breast cancer. This 
methodology however has not been applied to cancerous tissue samples and 
therefore we used the blood from patients with haematological cancers as a 
cancer tissue model for genetic toxicity.  
1.1 Haematological Cancers 
Cancer is characterised aberrant cell growth, facilitating the potential to invade 
surrounding tissue or metastasise to other parts of the body. It is a multifactorial 
process, resulting from the accumulation of mutations leading to the dysfunction 
of normal cellular function. Haematological malignancies are a diverse group of 
cancers originating in the bone marrow or lymphatic system. As the circulatory 
and immune systems are closely linked, the effects of the disease are likely to 
be reflected in other systems. The main categories include leukaemia, 
lymphoma and myeloma, however many sub-groups exist. The greatest 
incidence in haematological cancers are seen in the elderly, however, the exact 
aetiology is unknown. There is a number of risk factors that can increase the 
likelihood of the development of a haematological malignancy including 
exposure to ionising radiation, chemicals and dusts, smoking, viral infection, 
genetic predisposition and Downs syndrome. Haematological malignancies 
accounted for 8.4% of all malignant disease diagnoses in England during 2001-
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2010 with the incidence of Hodgkin lymphoma, non-Hodgkin lymphoma and 
myeloma increasing over that period, with no haematological cancers 
experiencing a decline in incidence (PHE, 2014).   
1.2 Hydrocortisone and cancer therapy 
Hydrocortisone (HC) is an agent belonging to the steroid hormone family, 
namely glucocorticoids (GCs). It is commonly used in the treatment of 
lymphomas, leukaemia’s, myelomas and for relief of certain symptoms arising 
from other cancer. HC mediates its action either directly or indirectly through the 
glucocorticoid receptor (GR) which, upon activation, is able to alter signalling 
pathways within the cell and translocates to the nucleus where it acts as a 
transcription factor influencing processes such as proliferation, differentiation 
and apoptosis (Schlossmacher et al., 2011). The anti-inflammatory and 
immunosuppressive properties of GCs have also been crucial to cancer 
treatment. The link between cancer and inflammation has been extensively 
reviewed (Rakoff-Nahoum, 2006) in which they conclude that chronic 
inflammation can predispose an individual to cancer through exposure to 
inflammatory mediators that leads to increased cell proliferation, mutagenesis 
and can influence tumour progression and metastasis. GCs are able to both 
inhibit initial events in the inflammatory response as well as promote resolution 
of inflammation. These are as a result of the transcriptional effects of GR 
agonism which results in the activation and repression of a number of different 
genes in leukocytes. GR mediated transrepression (protein-protein binding of 
GR with target) of pro-inflammatory transcription factors, nuclear factor kappaB 
(NF-kB) and activating protein 1 (AP1) results in the down regulation of 
inflammatory mediators (Clark, 2007). Transcriptional activation of a number of 
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anti-inflammatory mediators, including dual specificity phosphatase 1 (DUSP1), 
by GR has also been implicated in the anti-inflammatory effect of GCs 
(Coutinho and Chapman, 2011). The above effects have resulted in HC being 
incorporated into chemotherapeutic regimes; however, prolonged use has 
resulted in the development of resistance to the drug. The mechanism of this 
resistance is a result of genetic alterations in the GC gene resulting in aberrant 
GR being expressed that is unable to bind GCs and therefore their therapeutic 
potential is reduced or lost (Moalli and Rosen, 1994). This emphasises the need 
to modify current pharmaceuticals to prolong their use in cases of resistance 
and therefore nanotechnology may provide the answer to overcome the 
resistance and tolerance to HC and in doing so may enhance its intrinsic 
properties.  
1.2.1 Hydrocortisone nano suspensions in current use 
HC is widely used as a treatment for various conditions including eye and ear 
inflammation, allergic reactions and inflammatory skin disorders.  The 
introduction of nanotechnology has provided an opportunity to enhance existing 
treatments. Reis et al. (2013) and Katas et al. (2012) demonstrated that using 
biodegradable polymeric NPs and chitosan NPs to deliver HC respectively, 
greatly improved the treatment of atopic dermatitis, a chronic inflammatory skin 
disorder. They found that hydrocortisone-loaded NPs were more stable against 
degradation and therefore lead to prolonged release of the drug with a more 
targeted approach increasing specificity and bioavailability.  The uniform particle 
size exhibited led to an increase in skin penetration and a reduced toxicological 
profile. Both studies illustrate the potential of these NPs as delivery systems for 
anti-inflammatory drugs that could improve efficacy and reduce adverse effects. 
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Similar results were reported by Ali et al. (2011) in the use of HC 
nanosuspensions for ophthalmic delivery. In current topical treatments, poor 
solubility displayed by HC resulted in low corneal permeability and 
bioavailability.  During this study, HC nanosuspensions were developed using 
microfluidic nanoprecipitation and wet milling procedures. When tested in 
rabbits, the nanosuspensions demonstrated enhanced bioavailability and 
sustained action when compared to the HC solution. This highlights the 
potential to decrease the frequency of administration and therefore improve 
patient compliance of ocular treatments.  Albumin NPs coated with HC were 
also shown to increase the drug concentration in the pre-corneal target area 
whilst enabling the targeting of HC away from the inner compartments of the 
eye where intraocular pressure resulted in adverse side effects in the inflamed 
eye (Zimmer et al., 1994).  
1.3 NSAIDs 
In 400 B.C the Greek physician Hippocrates prescribed the extract of willow 
bark for the treatment of fever and inflammation. It was later found that the 
active ingredient responsible for the therapeutic effects was salicin, which led to 
the production of salicylic acid and its derivatives, known as NSAIDs (Rao and 
Knaus, 2008). NSAIDs are now some of the most commonly used drugs 
worldwide with analgesic, antipyretic and anti-inflammatory applications. More 
recently it has been shown that NSAIDs are potential therapeutic agents in the 
treatment and prevention of cancer and certain neurological disorders (Bacchi 
et al., 2012). The use of NSAIDs is not without adverse effects such as 
gastrointestinal (GI) complications, cardiovascular events and renal toxicity, 
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which severely hinders their potential. The two NSAIDs used in this study 
include acetylsalicylic acid (aspirin) and the aryl-propionic acid, ibuprofen.  
1.3.1 Mechanism of NSAID action  
The mechanism of NSAID action was initially described by Vane (1971) as an 
inhibitor of prostanoids through inhibition of the cyclo-oxygenase (COX) enzyme 
and this was then further expanded to include the presence of COX-2 by 
Simmons et al. (2004). Prostaglandins (PGs) are produced via the COX 
pathway (fig. 1-1) through the metabolism of fatty acids and are implicated as 
mediators during inflammation, pain, fever and the development of cancer and 
certain neurological disorders (Bacchi et al., 2012). COX has two isoforms 
produced by different genes that are similar in structure however have different 
intracellular locations and substrate/inhibitor selectivity. COX-1 is constitutively 
expressed and functions as a housekeeping enzyme, responsible for the 
regulation of a number of cell functions, including preserving the integrity of the 
gastric mucosa and maintaining platelet and kidney function. The COX-2 
enzyme is highly inducible by pro-inflammatory cytokines and growth factors 
such as interferon γ, tumour necrosis factor α and interleukin 1, revealing a role 
for COX-2 in inflammation and the control of cellular growth (Vane et al., 1998). 
Arachidonic acid, a fatty acid embedded in cell membranes, is the precursor to 
PG and thromboxane synthesis. Through the inhibition of these COX enzymes, 
a reduction is PG synthesis is observed, subsequently reducing in pain and 
inflammation through the decrease in vasodilating PGs (PGE2 and PGI2) 
(Simmons et al., 2004).  
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Figure 1-1 Prostaglandin synthesis 
Prostaglandin synthesis showing the COX pathway. Figure from Bacchi et al. 
(2012) 
1.3.2 NSAIDs and Cancer  
The association of aspirin with anti-metastatic effects was initially demonstrated 
when the relationship between platelet levels and metastasis was investigated. 
It was found that reduced platelet levels inhibited the spread of a number of 
different experimental malignancies and therefore a direct correlation between 
the ability of a tumour to promote platelet aggregation and its capacity for 
metastasis was revealed (Gasic et al., 1968). Gay and Felding-Habermann 
(2011) demonstrated that platelets were able to guard circulating tumour cells 
from the immune system and promote their arrest at the endothelium enabling 
the establishment of secondary tumours. Due to the association of 
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thrombocytopenia with reduced metastasis, aspirin and other drugs that inhibit 
platelet aggregation were found to significantly reduce the ability of a tumour to 
metastasise (Gasic et al., 1973), illustrating the potential of these drugs to limit 
the progression of cancer. Bennett et al. (1977) established that prostaglandins 
(PGs) were important for the growth of tumours and that abnormal PG synthesis 
is characteristic of malignant cells and therefore the benefit seen with aspirin 
treatment was mediated through the inhibition of the COX enzyme which are 
responsible for prostaglandin synthesis. Randomised trials for the prevention of 
cardiovascular disease entailed a daily aspirin dose (≥75mg daily) versus 
control which enabled the effect of daily aspirin on the risk of cancer metastasis 
to be determined. Results from these trials showed that daily aspirin reduced 
the risk of distant metastasis by 30%-40%, with a 70% reduced metastasis risk 
and an overall reduction in deaths in patients with adenocarcinoma that did not 
have metastasis at diagnosis and remained on treatment for the duration of the 
trial (Rothwell et al., 2012). This suggests that the effect of aspirin on invasive 
cancer and cancer death occurs relatively early in carcinogenesis and that 
aspirin may also have an effect on the growth, spread and initiation of tumours 
(Chan and Cook, 2012).  
Through meta-analysis of randomised controlled trials, Flossmann and Rothwell 
(2007) were able to demonstrate that the allocation to ≥300mg of aspirin or 
related NSAIDs daily for 5 years or more reduced the incidence of colorectal 
cancer after a latency of 10 years. Long—term follow up of individual patient 
data indicated that daily aspirin reduced the risk of death due to colorectal 
cancer by 20% and this was maintained at a 20-year follow up (Rothwell et al., 
2010b). Further studies indicated that the benefit from aspirin treatment 
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increased with the duration of treatment and also extended to other common 
cancers including oesophageal, brain and lung cancer, with a latent period of 5 
years (Rothwell et al., 2011). Recently, Streicher et al. (2014) reported the 
relationship between aspirin use and decreased pancreatic cancer incidence 
and mortality which is significant in light of the 5 year survival rate of less than 
5% for pancreatic cancer.  Analysis of observational studies on aspirin and the 
risk of cancer by Bosetti et al. (2012) confirmed the protective effect for 
colorectal cancer and other cancers of the digestive tract with a modest risk 
reduction for breast and prostate cancer. Data on lung cancer was inconclusive 
however and they failed to find a protective association with pancreatic, 
endometrial, ovarian, bladder and kidney cancer. Conflicting results were seen 
from Sturmer et al. (1998) and Cook et al. (2005) who failed to find an 
association between aspirin use and the risk of cancer, however low aspirin 
dose with short treatment time and alternative day use respectively could 
possibly account for these findings. 
The discovery that expression of COX-2 was upregulated in cancerous tissue 
and associated with enhanced invasiveness, increased mutagenesis and 
proliferation mediated by PGE2 and the production of reactive oxygen species 
(ROS) lead to interest in NSAIDs as a means of treating and preventing 
different types of cancer (Kanaoka et al., 2007, Sobolewski et al., 2010). The 
use of selective COX-2 inhibitors was of great interest, however the association 
of the anti-cancer effects of platelet deactivation through COX-1 inhibition 
further added to the effectiveness of NSAIDs as a cancer preventative (Nash et 
al., 2002). Aspirin is currently the only drug to permanently inhibit COX-1 and 
COX-2 activity. Other anti-cancer effects consist of both COX-dependent 
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(inhibition of sphingosine-1-phosphate (S1-P) production and activation of the 
NSAID-induced gene (NAG-1)) and independent mechanisms (regulate the 
activation of nuclear factor kappa B (NF-κB)) and are extensively reviewed in 
(Stolfi et al., 2013, Ruegg et al., 2003). 
1.4 Nanotechnology 
Nanotechnology is the study, understanding and manipulation of matter at 
dimensions between 1 and 1000 nanometers. At this nanoscale, matter exhibits 
properties distinct from the bulk material including biological, physical and 
chemical characteristics which provides a platform where all these disciplines 
converge. It is only recently that scientists have gained the ability to visualise 
these particles and in doing so acquired the means to take advantage of their 
unique properties that occur at this scale. Nanoparticles (NPs) have a greater 
surface area to volume ratio than larger scale materials which allows for more 
contact between the nanoparticle and the surrounding material resulting in an 
increased surface energy and improved reactivity (Chan, 2006). These quantum 
effects seen as a result of particle size affect properties such as electrical and 
heat conductivity, chemical reactivity and dissolution (Chan, 2006). The endless 
possibilities generated by nanotechnology have caused much interest in 
medicine, electronics, engineering and power generation resulting in a rapidly 
developing and innovative field. Working at the nanoscale provides the 
opportunity to modify fundamental properties of the material including delivery, 
immunogenicity and diffusivity. This manipulation at the nanoscale provides the 
opportunity to produce medicine with greater dissolution with alternative routes 
of administration and more targeted delivery systems which can reduce 
therapeutic toxicity and extend the drugs circulatory half-life leading to reduced 
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health-care costs (Zhang et al., 2007).  The implications of nanomedicine are 
vast with the potential to improve diagnosis, imaging and treatment of disease 
however the safety of these particles has not been extensively studied with 
concerns raised over toxicity and environmental impact. Nanoparticles can be 
inhaled, ingested, injected and absorbed through the skin and the increased 
use of nanoparticles in manufacturing and industry leads to an increase in 
exposure rate therefore the adverse effects of nanoparticles to living cells 
requires further attention and investigations (Oberdörster et al., 2005). An 
understanding of the genotoxic effects of specific nanoparticles on human cells 
and the mechanisms of this toxicity is vital when considering reducing a bulk 
compound to the nanoscale. 
1.4.1 Applications of nanoparticles in medicine 
By reducing the size of compounds, therapeutic properties not exhibited by the 
bulk compound may be present at the nanoscale despite having the same 
chemical composition and formula. This broadens the application potential of 
current agents and therefore much research is focused understanding the 
behaviour of material at this scale. Nanotechnology has greatly contributed to 
the development of drugs in cancer therapy and neurological disorders due to 
the ability of the particles to cross normally impermeable barriers such as the 
blood-brain barrier and tumour pores. The increased surface area of the particle 
enhances the solubility and rate of dissolution resulting in increased 
bioavailability and rapid onset of therapeutic action (Chan, 2006). The increased 
reactivity of drugs allows for reduced concentrations to be used thereby 
reducing the potential adverse reactions to potent drugs. Damm et al. (2008) 
demonstrated that silver nanoparticles had a much higher antimicrobial efficacy 
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than silver micro particles. The rate of silver ion release in the nanoparticles 
was deemed to be an order of magnitude higher than the micro particle due to 
the larger surface area of the nanoparticle and as such silver nanoparticles are 
used in infection prevention and wound healing.  
Significant applications of nanoparticles lie in biochemical imaging, drug 
delivery, gene therapy and tissue engineering (Salata, 2004). The modification 
potential of the particles allow them to act as a platform for the assembly of 
multifunctional structures that can be used in drug targeting, sensing and 
imaging. The size and shape of the nanoparticles can be altered according to 
the desired drug payload and can also influence the cellular uptake and 
retention of drugs. Nanoparticle drug-delivery systems can convey drugs more 
efficiently and conveniently than current methods and in doing so increase 
patient compliance and drug shelf life with increased drug pharmacokinetics. 
Semiconductor and metallic nanostructures provide a mechanism in which 
optical properties can be altered by a change in size resulting in a change in 
emission wavelengths which facilitates biomedical imaging (Doane and Burda, 
2012, Parveen et al., 2012). The properties of NP’s as a result of their specific 
surface area result in an enhanced ability of adsorption, concentration and 
protection of DNA and RNA making them ideal gene delivery vectors (Sun et 
al., 2014) with modified gold nanometre gene vectors being extensively studied 
in relation to tumour treatment due to their transfection efficiency.   
1.4.2 Hydrocortisone nano suspensions in current use 
HC is widely used as a treatment for various conditions including eye and ear 
inflammation, allergic reactions and inflammatory skin disorders.  The 
introduction of nanotechnology has provided an opportunity to enhance existing 
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treatments. Reis et al. (2013) and Katas et al. (2012) demonstrated that using 
biodegradable polymeric NPs and chitosan NPs to deliver HC respectively, 
greatly improved the treatment of atopic dermatitis, a chronic inflammatory skin 
disorder. They found that hydrocortisone-loaded NPs were more stable against 
degradation and therefore lead to prolonged release of the drug with a more 
targeted approach increasing specificity and bioavailability.  The uniform particle 
size exhibited led to an increase in skin penetration and a reduced toxicological 
profile. Both studies illustrate the potential of these NPs as delivery systems for 
anti-inflammatory drugs that could improve efficacy and reduce adverse effects. 
Similar results were reported by Ali et al. (2011) in the use of HC 
nanosuspensions for ophthalmic delivery. In current topical treatments, poor 
solubility displayed by HC resulted in low corneal permeability and 
bioavailability.  During this study, HC nanosuspensions were developed using 
microfluidic nanoprecipitation and wet milling procedures. When tested in 
rabbits, the nanosuspensions demonstrated enhanced bioavailability and 
sustained action when compared to the HC solution. This highlights the 
potential to decrease the frequency of administration and therefore improve 
patient compliance of ocular treatments.  Albumin NPs coated with HC were 
also shown to increase the drug concentration in the pre-corneal target area 
whilst enabling the targeting of HC away from the inner compartments of the 
eye where intraocular pressure resulted in adverse side effects in the inflamed 
eye (Zimmer et al., 1994).  
1.4.3 Size dependent toxicity 
Alterations are seen in the physical and chemical properties of particles, as their 
size is deceased from the bulk material to the nanoscale with materials 
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becoming more reactive with an enhancement of their intrinsic properties 
causing changes in their biological effects. Engineered gold nanoparticles are 
associated with amplified electrical, chemical, mechanical, thermal and optical 
properties which differ drastically from the bio-inert bulk counterpart (Yah, 
2013), however, this increased reactivity is accompanied by an increase in 
toxicity. This phenomenon was demonstrated when non-toxic gold particles 
were reduced to their nanoform resulting in increased toxic effects in living cells 
(Chen et al., 2009). Treatment of BALB/C mice with gold nanoparticles (AuNPs) 
from 8-37nm resulted in fatigue, alterations in the colour of their fur, loss of 
appetite and weight loss which was found to be caused by damage to the liver, 
lungs and spleen. The majority of the mice treated died within 21 days. 
Treatment of mice with AuNPs of 3-5nm and 50-100nm proved to be non-toxic 
due to the initiation of a sufficient antibody response and diffusion-restricted 
effects respectively. Modifications to the surface of AuNPs (8-37nm) with 
immunogenic peptides resulted in reduced toxicity suggesting that the toxicity 
exhibited by AuNPs was due to their inability to elicit an immunological 
response and ability of the nanoparticles to diffuse freely into the cells. Gerber 
et al. (2013) and Yah (2013) extensively reviewed the toxicity associated with 
AuNPs that includes implicating AuNPs as developmental hazards to mammals 
through embryo lethality and morphological effects in zebra fish and as a 
genetic mutagen in the germ line of Drosophila that may be inherited by 
progeny. Gerber et al. (2013) also described increased toxicity associated with 
a stressed liver environment by accelerating stress-induced apoptosis and 
stimulating the inflammatory response further highlighting the importance of 
investigating the particle size, surface chemistry and charge that are crucial to 
16 
 
the development of toxicity. Further evidence of the difference in toxicity 
displayed by nanoparticles and their bulk counterparts was seen in copper 
oxide (CuO) nanoparticles, which are increasingly being used in biocides. 
During acute and chronic toxicity testing in Daphnia magna, ten times higher 
toxicity was seen in CuO NPs than CuO micro particles with a similar affect 
seen in Vibrio fischeri (Rossetto et al., 2014). Mice treated with carbon 
nanotubes exhibited dose-dependent epithelioid granulomas, interstitial 
inflammation, peribronchial inflammation and necrosis whereas treatment with 
carbon black induced no toxic effects. The effect exhibited by the carbon 
nanotubes was comparable to effects seen with treatment with the positive 
control quartz, which is considered an occupational health hazard in chronic 
inhalation exposures (Lam et al., 2004). This highlights the importance of 
classifying materials based on their bulk and nano characteristics separately.  
1.4.4 Nano particles and Cell interactions 
Large-scale dissipative particle dynamics simulations revealed three main 
pathways in which NPs enter cells namely spontaneous penetration for very 
small NPs (diameter <4.5nm ), endocytosis and semi-endocytosis for larger 
NPs (diameter >4.5nm ) (Chen et al., 2013). The spontaneous penetration 
pathway is comprised of three methods of NP internalisation including direct 
penetration, inverted micelle-like penetration and cooperative chain-like 
penetration.  The adsorption and internalisation of NP were also found to affect 
the integrity of vesicles as clustering of NP on the vesicle surface lead to 
various morphological changes and even vesicle rupture. Other adverse effects 
of NP internalisation indicated that the hydrophilic pore produced during direct 
penetration may allow leakage of intracellular water.  Shang et al. (2014) 
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described the interaction of NP with biomolecules present in bodily fluids such 
as proteins, sugars and lipids. These biomolecules can coat the surface of the 
NP and form a protein corona which is able to adapt to varying conditions and 
concentrations of biomolecules and therefore their composition is not static 
which establishes the identity for the NP. This is influenced by various 
properties of the NP including surface chemistry, size, shape and charge. The 
protein corona facilitates varying interactions with cells and their receptors 
which could result in the NP being internalised through pinocytosis when a 
strong interaction is made with surface receptors.  Once internalised, NPs may 
be able to reach the nucleus through diffusion across the nuclear membrane or 
be actively transported through a nuclear pore allowing direct interaction with 
DNA (Magdolenova et al., 2013). This demonstrates that the size and surface 
properties of NPs have a strong influence on the method of internalisation, 
uptake efficiency and cytotoxicity when interacting with living cells.  
1.4.5 Nanoparticle toxicity 
The mechanisms of NP toxicity are extensively reviewed by Magdolenova et al. 
(2013) and Manke et al. (2013) and can be described as either direct/indirect 
primary or secondary genotoxicty. This includes generation of reactive oxygen 
species (ROS), oxidative stress, inflammation, genetic damage and inhibition of 
the cell cycle and apoptosis.  Conflicting results have been published detailing 
NP genotoxicity therefore for the mechanisms of toxicity to be interpreted 
accurately, the physico-chemical properties of NPs must be established 
including particle shape, size, composition, crystalline structure, solubility, 
surface area and properties as well as the agglomeration potential 
(Magdolenova et al. 2013). 
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1.4.6 Primary genotoxicity 
Direct primary genotoxicity involves the direct interaction of NPs with DNA or 
chromosomes. NPs that are able to enter the nucleus (fig 1-2) may interfere 
with DNA replication, transcription and repair through either mechanical 
disruption or chemically binding to the DNA molecules causing structural 
damage and DNA instability. During mitosis these NPs could introduce 
breakage to chromosomes and interfere with the progression of mitosis. Li et al. 
(2013) were able to determine that NPs with a high binding affinity for DNA 
produced a strong inhibitory effect on replication. They were able to 
demonstrate that quantum dots and hematite NPs were able to bind to DNA and 
alter its conformation and that silver and ZnO NPs in particular formed a very 
compact DNA conformation. This could result in nuclear proteins that are 
required for transcription, translation or repair not being able to access the 
relevant DNA binding sites due to NPs occupying the sites directly or through 
conformational changes of the DNA restricting access or altering spatial 
relationships. The genotoxic effects that arise from NPs do not always require 
the NP to be in direct contact with the DNA and therefore can induce toxicity 
indirectly. Indirect primary genotoxicity may arise through a number of different 
mechanisms including interaction with nuclear proteins, interaction with the 
mitotic machinery, disruption of the cell cycle, ROS generation, transition metal 
formation and inhibition of the antioxidant defence (Magdolenova et al., 2013). 
Silica NPs were shown to form aberrant inclusions in the nucleus containing 
various proteins including topoisomerase 1, CBP and polyQ. The result of these 
protein aggregates was inhibition of replication, transcription and cell 
proliferation (Chen and von Mikecz, 2005). 
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Figure 1-2 Internalisation of NP and access to the nucleus 
Diagram illustrating the different routes that NPs become internalised into the 
nucleus of cells (Magdolenova et al. 2013). 
1.4.6.1 Nanoparticle mediated oxidative stress 
Studies have shown a direct correlation between ROS levels and consequent 
oxidative stress in NP toxicity (fig 1-3) (Manke et al. 2013). Oxidative stress can 
result from either excessive ROS generation or depletion of cellular antioxidant 
capacity. NP mediated ROS generation is said to be linked to the surface 
properties and size of the NP. Dissolution of the NP and the subsequent release 
of metal ions and the presence of transition metal on the surface are able to 
catalyse ROS generation (Li et al., 2008).  ROS generation, whether 
endogenous or exogenous, result in the production of free radicals including the 
superoxide anion and hydroxyl radical that are capable of interacting with and 
causing damage to DNA and other cellular compartments (Akhtar et al., 2012, 
Fu et al., 2014). The interaction of ROS with DNA may result in oxidised base 
lesions and strand breaks leading to the introduction of mutation or cell death 
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(Magdolenova et al. 2013). Toxic levels of these free radicals cause membrane 
damage and electron chain dysfunction leading to the mitochondrial apoptotic 
pathway. NPs can contribute to this ROS generation by blocking the electron 
transport chain of the mitochondria or catalysing the transfer of electrons to 
molecular oxygen (Manke et al. 2013). Ahmad et al. (2012) described the 
relationship between ROS generation and cellular death following the treatment 
of HepG2 cells with silica NPs. Protein and mRNA levels of apoptotic genes 
p53, bax and caspase-3 were elevated after exposure to silica NP and a 
reduction in expression of antioxidant GSH and the anti-apoptotic gene bcl-2 
was seen leading to apoptosis. The alterations induced by the silica NPs were 
attenuated by treatment with the ROS scavenger vitamin C leading to an 
increase in cell viability and demonstrating that ROS play a vital role in NP 
medicated cytotoxicity. There is also a clear association between NP medicated 
ROS generation and the disruption of cellular calcium homeostasis. Calcium 
plays an important role in cellular metabolism, signal transduction and gene 
expression and therefore intracellular calcium levels are tightly regulated with 
an increase in intracellular calcium resulting in cellular dysfunction, metabolic 
imbalance and cell death. Huang et al. (2010) demonstrated a concentration-
dependent increase in intracellular calcium in cells treated with ZnO NPs that 
resulted in cell death. This affect was partially attenuated with the treatment of 
the antioxidant N-acetylcysteine (NAC) and cytotoxicity completely abolished 
illustrating the effect of oxidative stress on calcium homeostasis.  
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Figure 1-3 Pro-oxidant pathway 
Pro-oxidant pathway for NP-induced toxicity: NP exhibit oxidative stress dependent toxicity 
(Manke et al. 2013). 
 
1.4.7 Secondary genotoxicity 
NPs have also been shown to generate ROS and RNS (reactive nitrogen 
species) in phagocytes through the initiation of inflammation that is able to 
overwhelm antioxidant and DNA repair mechanisms (Schins, 2013) and 
therefore suggests that secondary genotoxicity contains a threshold that must 
be overcome with a significant dose and duration of exposure (Schins, 2002). 
Trouiller et al. (2009) found that changes in cytokine expression in peripheral 
blood of mice were a result of an inflammatory reaction caused by TiO2 NPs. 
This pro-inflammatory activity leads to the activation of phagocytes resulting in 
oxidative bursts to eliminate NPs, leading to genotoxicity. Pro-inflammatory 
gene transcription factors (MAP kinases, NF-KB and AP-1) have also been 
activated in response to NP treatment (Donaldson et al., 2012). Park and Park 
(2009) reported activation of peritoneal macrophages after treatment of mice 
and the RAW264.7 cell line with silica NPs leading to the release of  increased 
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levels of IL-1β, TNF-α and nitric oxide. This correlated with an increased mRNA 
expression of inflammatory genes from with the macrophages including IL-6, 
TNF-α, nitric oxide and COX-2. Treatment of the RAW264.7 cell line revealed 
ROS generation with a decreased expression of antioxidant glutathione (GSH) 
further indicating that NPs generate ROS which in turn trigger the expression of 
pro-inflammatory mediators leading to the activation of immune cells and the 
resulting ROS generation contributes significantly to genotoxicity.  
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2 Materials and Methods  
2.1 Ethical approval  
This study received approval from Leeds East Research Ethics Committee 
(REC number: 12/YH/0464), the University of Bradford Research Ethics Sub-
Committee on Research in Human Subjects (Ref: 0405/8) and the Research 
Support and Governance office, Bradford Teaching Hospitals, NHS Foundation 
(Ref: RE DA 1202).  
2.2 Whole-blood collection and processing 
Whole blood was collected by venepuncture into lithium heparin Vacuette 
containers from healthy individuals and patients with haematological cancers. 
Healthy control individuals were recruited from the University of Bradford. 
Cancer patients were recruited from the Haematology clinic of Dr Lisa Newton, 
Consultant Haematologist from Bradford Teaching Hospitals NHS Foundation 
Trust. Characteristics of patients and healthy individuals are shown in appendix 
2.  Blood samples were collected after obtaining informed consent (Appendix 3) 
from the patients and volunteers; a questionnaire (Appendix 4) was also 
completed prior to sample collection and an information sheet provided 
(Appendix 5). After collection, blood samples were diluted with RPMI-1640 
media (1:1 dilution) and supplemented with dimethyl sulfoxide (DMSO, 10% of 
the final volume). The sample was then separated into 1 ml aliquots and frozen 
at -80 °C until required.  
2.3 Chemicals 
All chemicals used in this study including source and CAS number are 
summarised in table 2-1. The drugs aspirin, ibuprofen and hydrocortisone were 
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tested at two particle sizes each, in their bulk form and its nano-sized 
counterpart to evaluate the effect of particle size on toxicity.   
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Table 2-1 Chemicals and sources 
Chemical Supplier CAS Number 
Aspirin Sigma-Aldrich, UK 50-78-2 
Cytochalastin-B Sigma-Aldrich, UK 14930-96-2 
Dimethyl sulfoxide Sigma-Aldrich, UK 67-68-5 
DPX Mountant Sigma-Aldrich, UK - 
Ethanol Sigma-Aldrich, UK 64-17-5 
Ethidium bromide Sigma-Aldrich, UK 1239-45-8 
Formaldehyde Sigma-Aldrich, UK 50-00-0 
Foetal Bovine Serum Gibco, Thermo Fisher Scientific N/A 
Giemsa stain VWR 51811-82-6 
Glacial Acetic Acid Sigma-Aldrich, UK 64-19-7 
Hydrocortisone Alfa Aesar 50-23-7 
Hydrogen peroxide Sigma-Aldrich, UK 7722-84-1 
Ibuprofen Albermarle sprt 15687-27-1 
Low melting point agarose Invitrogen, UK 39346-81-1 
Methanol Fisher Scientific, UK 67-56-1 
Mitomycin C Sigma-Aldrich, UK 50-07-7 
Na2EDTA 20 Fisher Scientific, UK 6381-92-6 
NaCl Sigma-Aldrich, UK 7647-14-5 
NaOH Fisher Scientific, UK 1310-73-2 
Normal melting point agarose Invitrogen, UK 9012-36-6 
Penicillin-Streptomycin Invitrogen, UK - 
Phosphate Buffered Saline Sigma-Aldrich, UK N/A 
Phytohemagglutinin, M form Gibco, Thermo Fisher Scientific 9008-97-3 
Potassium chloride VWR 7447-40-7 
RPMI-1640 Medium Sigma-Aldrich, UK N/A 
RPMI Medium 1640  + GlutaMAX-I Gibco, Thermo Fisher Scientific N/A 
Sodium phosphate dibasic Sigma-Aldrich, UK 7558-80-7 
Sodium phonsphate monobasic Acros Organics 7558-80-7 
Tris Base Fisher Scientific, UK 77-86-1 
Triton X-100 Fisher Scientific, UK 9002-93-1 
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2.4 Preparation of nano-material 
Suspensions of aspirin, ibuprofen and hydrocortisone were prepared with solid 
loads of 5%, 4% and 3%  (W/W) respectively. The suspending medium 
consisted of hydroxypropyl methylcellulose (0.5% w/w), sodium lauryl sulphate 
(0.1% W/W) and polyvinylpyrrolidone K-30 (0.5%, w/w) in deionised water 
(Plakkot et al., 2011). Milling of the suspensions was carried out on a Lena 
Nanoceutics technology DM-100 machine (Sulaiman, 2007). Each suspension 
(250 ml each) was milled for 60 minutes using 150 ml of 0.2 mm yttrium 
stabilised zirconium beads (Glen Mills, USA).  Solutions were stored in opaque 
glass bottles at 4 °C for the duration of the experiment and sonicated for 15 
minutes prior to use.  
2.5 Zeta potential 
Zeta potential is one of the fundamental parameters known to affect the stability 
of a suspension. It is a measure of the magnitude of the electrostatic potential 
between particles. The zeta potential was measured using a Zetasizer Nano ZS 
(Malvern Instruments, UK) after the suspensions were diluted 1:100 using 
deionised water at 25 °C. Clear disposable zeta cells were used with automatic 
measurement duration between 10 and 100 runs with all measurements made 
in triplicate.  
2.6 Particle size  
The Dynamic Light Scattering technique of the Zetasizer Nano ZS (Malvern 
Instruments, UK) was used to determine the particle size of aspirin, ibuprofen 
and hydrocortisone nano-suspensions. All measurements were carried out in 
triplicate using disposable sizing cuvettes at room temperature. The particle 
size of the suspensions were measured immediately after milling and then 
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rechecked at the end of experiments to ensure the particle size has not 
significantly changed during the course of the experiment. The particle size of 
the bulk powder was measured using laser diffraction (Sympatec Helos, UK). 
Approximately 20mg of each drug was transferred to the sample vial. Whilst the 
feeder was running at 40 mm/s, the primary pressure was adjusted to 4 bars 
with triplicate measurements taken using an R2 lens (0.25/0.45, 87.5 µm) 
2.7 The alkaline comet assay 
The alkaline (pH >13) version of the comet assay (SCGE) was used to 
determine the extent of DNA damage and was performed in accordance with 
the International Workgroup on Genotoxicity Testing guidelines (Tice et al., 
2000) and as described by Singh et al. (1988). Stored whole blood from 12 
healthy volunteers and 19 patients with haematological cancers were used in 
this assay. Frozen samples were allowed to thaw at room temperature prior to 
use.   
2.7.1 Cell Treatment  
90 µl of whole blood was incubated for 30 minutes at 37°C with various test 
agents, made up to a final volume of 1ml with RPMI 1640 media. The test 
agents included a positive control of 50 µM hydrogen peroxide, aspirin at 500 
µg/ml, ibuprofen at 500 µg/ml and hydrocortisone at 50 µg/ml. Optimal doses 
from each drug were determined from preliminary studies in our laboratory 
(unpublished data). Aspirin, ibuprofen and hydrocortisone were tested in their 
bulk and nano forms at corresponding doses. To test the effect of 
hydrocortisone in a highly oxidising environment, 50 µg/ml of hydrocortisone 
(both bulk and nano) were co-treated with 50µM hydrogen peroxide. An 
untreated sample was used as a negative control. Immediately after incubation, 
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samples were centrifuged at 3000 rpm for 5 minutes and 900 µl of the 
supernatant discarded. The remaining pellet was then re-suspended in 0.5% 
low melting point agarose (40°C in PBS) and 100 µl of the suspension was 
added to coded slides pre-coated with agarose (1% normal melting point 
agarose). Coverslips were placed on the slides and gels allowed to set for 5 
minutes on ice. Coverslips were removed and slides incubated overnight in 
freshly prepared lysis solution (2.5 M NaCl, 100mM EDTA, 10 mM Trizma base, 
10% DMSO and 1% Triton X-100, pH 10) at 4°C in order to disrupt proteins, 
RNA and membranes. After lysis, the slides were transferred to a horizontal 
electrophoresis tank and incubated in freshly prepared alkaline electrophoresis 
buffer (10M NaOH and 200mM EDTA, pH >13) for 30 minutes at 4°C to 
facilitate the relaxation of supercoiled DNA, after which electrophoresis was 
performed at 25V, 300mAmps for 30 minutes. Slides were flooded with 
neutralisation buffer (0.4 M Tris-HCl, pH 7.5) 3 times for 5 minutes.  
2.7.2 Slide Staining and Scoring 
DNA was stained with the addition of 60µl ethidium bromide (20µg/ml) to each 
slide and a coverslip applied. Slides were stored in a sealed humidified box at 
4°C until scored. Slides were then coded to ensure blind scoring and one 
hundred nuclei per slide were scored using a fluorescent microscope at 200 X 
magnification, equipped with a CCD camera using Komet 6 software, Kinetic 
Imaging (Andor Technology Ltd, Belfast). Olive Tail Moment (OTM) and % Tail 
DNA were both used to reduce variability in results.  
2.8 The Cytokinesis Block Micronucleus (CBMN) Assay 
The cytokinesis-block micronucleus assay was used to measure DNA damage 
and cytostasis induced by the bulk and nano forms of aspirin, ibuprofen and 
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hydrocortisone. It was also used to compare the inherent DNA damage present 
in samples from cancer patients when compared to healthy individuals. Whole 
blood samples were collected from 5 healthy individuals and 5 haematological 
cancer patients. Cell culture was performed on fresh blood under sterile 
conditions.  
2.8.1 Cell Treatment 
Under sterile conditions, 4.5 ml of basic culture media (RPMI-1640 containing L-
Glutamine and 25 mM HEPES, 15% fetal bovine serum and 1% penicillin-
streptomycin solution) was added to T25 cm3 vented Corning culture flasks and 
frozen at -20 °C until required. The flasks were equilibrated at 37 °C (5% CO2) 
for 30 minutes prior to use. At the start of cell culture, 400 µl of fresh whole 
blood was added to each flask, together with 130 µl phytohaemagglutinin 
(PHA). Flasks were gently mixed and incubated for 24 hours at 37 °C (5% CO2). 
Chemical treatments were added at the following concentrations: Asp B and 
Asp N at 250 µg/ml, Ibu B and Ibu N at 125 µg/ml, HCB and HNC at 50 µg/ml 
and mitomycin C at 0.4 µM was used as a positive control. A negative control 
was also included, treated with RPMI-1640. The flasks were incubated for 20 
hours at 37 °C (5% CO2). In order to block cytokinesis, 30 µl of a 1mg/ml 
solution of cytochalasin-B was added to each flask and further incubated for 28 
hours at 37 °C (5% CO2). Contents of the flasks were transferred to 15 ml 
Falcon tubes.  
2.8.2 Cellular Fixation and Slide Preparation  
The tubes were centrifuged for 8 minutes at 800 rpm. Using a vacuum pump, 
the supernatant was removed and discarded, leaving 500 µl in the tube. 5 ml of 
a hypotonic solution (90 mM KCl at 4 °C) was slowly added to each flask whilst 
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gently mixing on a vortex mixer and incubated for 15 minutes at 4°C. The tubes 
were then centrifuged again and the supernatant discarded, leaving 500 µl. At 
this point the cells were ready for fixation. Fixation begins with the addition of 5 
ml freshly prepared Carnoy’s solution (1 part glacial acetic acid to 3 parts 
methanol), drop by drop whilst mixing gently on a vortex mixer followed by the 
addition of 3 drops of 38% formaldehyde to each tube. The tubes were 
centrifuged again as above and fixation repeated a further two times without the 
addition of formaldehyde. The supernatant was discarded, leaving 100 µl in the 
tube. Between 200-600 µl of fresh Carnoy’s solution was added to each tube, 
depending on the cell density and pellet size, checked using a phase contrast 
microscope. Four slides were prepared per treatment group with two 20 µl 
drops of cell suspension placed equal distances from the edges on each slide 
and left to air-dry overnight. Slides were stained with Giemsa in Sorenson buffer 
(5% Giemsa, phosphate buffer) for 20 minutes before being rinsed for 
approximately two minutes and left to air-dry overnight. Coverslips were 
mounted on to the stained slides using two drops of DPX Mountant on a heating 
block at 40 °C and left to set overnight.  
2.8.3 Cell Scoring 
A total of 1000 cells were scored per treatment group using bright-field 
microscopy at 400x magnification according to the criteria recommended by 
(Fenech, 2007, Fenech et al., 2003). The nuclear division index (NDI) is a 
measure of the proliferative status of the viable cells scored which provides an 
indication of the cytostatic effects and mitogenic response induced by the 
different treatments used. The NDI was calculated using the following 
calculation NDI = M1 + 2(M2) + 3(M3) / N where M1 = mononucleated cells, M2 
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= binucleated cells, M3 = multinucleated cells and N = total number of viable 
cells scored. Micronuclei (MN) were scored from binucleated (BiNC) and 
mononucleated cells (MonoNC). Nucleoplasmic bridges (NPBs) and nuclear 
buds (NBUDs) were only scored for BiNC. 
2.9 Statistical Analysis  
Statistical analysis was performed using GraphPad InStat 3.10 and GraphPad 
Prism software. Data were analysed by Kruskall Wallis one-way analysis of 
variance, followed by Dunnett’s multiple comparisons test (SCGE and CBMN 
assay) and the Mann-Whitney test, followed by the Wilcoxon matched pairs 
signed ranks test (anti-oxidant comet assay). P values of < 0.05 were 
considered statistically significant.  
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3 General results  
3.1 Particle size and stability 
The particle sizes of aspirin, ibuprofen and hydrocortisone nano-suspensions 
were determined using Dynamic Light Scattering (DLS). This is a well-
established method for measuring the size distribution of submicron particles in 
solution.  Following illumination of a sample with a laser, fluctuations of the 
scattered light are analysed and the size of the particles determined. This was 
performed prior to cell treatment and at monthly intervals thereafter for nano 
formulations to ensure particles remained in solution without aggregation.  The 
mean particle size of the bulk powders are listed in Table 3-2 and were obtained 
from the powders as received from the supplier. The mean particle size before 
and after treatment of nano suspensions was; aspirin: 289nm and 299nm; 
ibuprofen: 323nm and 340nm; and hydrocortisone: 248nm and 253nm, 
respectively (Table 3-1). The zeta potential was also measured to ensure the 
stability of the suspensions. The zeta potential is a measure of the magnitude of 
the electrostatic potential between particles with a higher zeta potential 
indicating a more stable solution able to resist aggregation whilst a low zeta 
potential demonstrates the tendency of a suspension to flocculate.  The zeta 
potential of the aspirin nano-solution was - 6.1mV (Table 3-1) indicating relative 
instability and the potential to aggregate therefore fresh suspensions were 
prepared monthly. Ibuprofen had a higher zeta potential (-2.1, table 3-1) 
indicating that it was more stable and although checked monthly, did not require 
fresh monthly preparations. The zeta potential data was not available for the 
hydrocortisone nano preparation however the particle size was checked 
monthly and appeared as stable as ibuprofen. Laser Diffraction was used to 
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determine the mean particle size of the bulk compounds. Aspirin had a mean 
particle size of 78.30μm, ibuprofen 52.80μm and hydrocortisone 5.98μm.  The 
following data have been generated by Dr M. Isreb, School of Pharmacy, The 
University of Bradford. 
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Table 3-1 Average particle size (x90) and the volume mean diameter of the bulk powder (as 
received) of aspirin, ibuprofen (n=3) and hydrocortisone. 
BulkPreparation  
 
Average particle size 
(μm)  
 
Volume Mean 
Diameter(μm)  
 
Aspirin  
 
78.30 ± 0.23  
 
44.57  
 
Ibuprofen  
 
52.80 ± 4.37  
 
20.50  
 
Hydrocortisone  5.98   
 
Table 3-2  Mean particle size, polydispersity index and zeta potential of nano-suspensions taken 
before and after cell treatment 
Suspension Time of 
measurement 
Mean 
particle size 
(nm) 
Polydispersity 
index (PDI) 
Zeta 
Potential 
(mV) 
Aspirin nano-
suspension 
5% 
Before cell 
treatment  
289 ± 3 0.3 ± 0.03 -6.1 
After cell 
treatment 
299 ± 6.3 0.3 ± 0.05  
Ibuprofen 
nano-
suspension 
4% 
Before cell 
treatment 
323 ± 6.4 0.2 ± 0.01 -2.1 
After cell 
treatment 
340 ± 1.2 0.3 ± 0.001  
Hydrocortisone 
nano-
suspension 
3% 
Before cell 
treatment 
248  0.2   
After cell 
treatment 
253  0.3   
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4 Genotoxicity of aspirin, ibuprofen and hydrocortisone bulk 
and nano particles on peripheral blood lymphocytes in the 
comet assay 
4.1 Introduction  
4.1.1 The comet assay 
The comet assay (single-cell gel electrophoresis) is one of the most commonly 
used assays for measuring genotoxicity and DNA repair. DNA damage and 
subsequent migration during electrophoresis exhibit the appearance of a comet 
with fragments of DNA migrating at a different speed to the nucleus. The higher 
molecular weight DNA in the nucleus forms the head of the comet with leading 
fragments of damaged DNA migrating at a faster rate forming the appearance 
of a comet tail. The tail consists of relaxed DNA loops with the tail intensity 
indicating the extent of DNA breaks and tail length indicating the length of the 
DNA loops (Collins et al., 1997). The assay was originally developed by Ostling 
and Johanson (1984), however, the neutral conditions described limited the 
scope of the assay and therefore Singh et al. (1988) introduced a modification 
to the technique that involved electrophoresis under alkaline conditions 
(pH>13). The alkaline comet assay resulted in increased DNA migration and 
therefore provided increased sensitivity for identifying genotoxic compounds. 
This increased migration is associated with increased levels of single strand 
beaks (SSB), incomplete excision repair sites; double strand breaks (DSB) and 
the conversion of alkaline labile sites (ALS) to SSB. Collins (2004) noted that 
SSB are rapidly repaired and not regarded as a significantly mutagenic lesion 
and therefore high levels of breaks in the comet assay could indicate either high 
levels of damage or efficient repair.  The specific repair mechanisms can be 
evaluated by treating the cells with lesion-specific repair endonucleases. The 
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comet assay provided clear advantages in genotoxicity studies when compared 
to the unscheduled DNA synthesis (UDS) assay and the alkaline elution assay. 
These included sensitivity for detecting low levels of DNA, small sample 
requirement, ease of use, cost and time effective, and flexibility in sample type 
(Tice et al., 2000). The comet assay is highly sensitive in detecting SSB, DSB 
and ALS; however, it is unable to readily detect DNA crosslinks. DNA crosslink 
are unique in their ability to stabilize DNA and inhibit its migration (Brendler-
Schwaab et al., 2005) and this can normally be identified by the degree of DNA 
migration being less than that for the negative control. These DNA crosslinks 
are highly relevant in mutagenesis and therefore on these occasions will require 
further work in the form of extending the electrophoresis time or treating a 
control and treated sample with an additional genotoxic agent and the migration 
in the presence and absence of this agent compared (Tice et al. 2000). Merk 
and Speit (1999) however revealed that this modified comet protocol while able 
to detect DNA-protein crosslinks; it was not well suited for the evaluation of 
DNA-DNA crosslinks and therefore leads to an underestimation of genotoxicity. 
The comet assay has also been employed in molecular epidemiology as a 
potential indicator of oxidative stress and carcinogenesis in human subjects. 
However, many lifestyle effects need to be considered when evaluating data as 
physical exercise and ageing have been found to contribute to increased DNA 
migration. Results are reported as olive tail moment (OTM) which represents 
the amount and distribution of DNA in the tail, together with the percentage of 
total DNA in the tail.   
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4.2 Experimental Aim 
In this experiment, we treated cryopreserved lymphocytes from healthy donors 
and patients with haematological cancers with aspirin, ibuprofen and 
hydrocortisone in the bulk and nanotised state. With the potential of nano-
medicine to enhance the efficacy of drugs, we sought to evaluate whether this 
increase in activity could lead to an increase in genetic insult. Previous studies 
from our laboratory using the comet assay indicate that the lymphocytes of 
patients diagnosed with cancer have increased sensitivity to genetic insult when 
exposed to ultra violet light (UVA) (Anderson et al., 2014). Further work 
revealed that this sensitivity extended to insult by DNA damaging agents 
(unpublished work) however the effect of these agents has not been assessed 
directly on cancerous cells. Performing he comet assay on lymphocytes from 
patients with haematological cancers enabled us to assess the direct result of 
the interaction of our target formulations with cancerous tissue.  
4.3 Materials and Methods 
All chemicals used in the comet assay are listed in Table 2.1. Methods are as 
described in section 2.3 and 2.7. Aspirin and ibuprofen (bulk and nano forms) 
were tested at 500 µg/ml each and hydrocortisone at 50 µg/ml. Bulk powders 
were freshly prepared before each experiment and solubilised in a suspending 
medium consisting of hydroxypropyl methylcellulose (0.5% w/w), sodium lauryl 
sulphate (0.1% W/W) and polyvinylpyrrolidone K-30 (0.5%, w/w) in deionised 
water. Nano particle solutions were more stable than the bulk solutions and 
therefore could be refrigerated at 4°C and sonicated for 15 minutes prior to use. 
The particle size was checked monthly to ensure particles did not agglutinate.   
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4.4 Results  
4.4.1 Genotoxicity of aspirin, ibuprofen and hydrocortisone (bulk and nano 
particles) on peripheral blood lymphocytes from healthy donors.  
The alkaline comet assay was used to determine the genotoxic potential of 
aspirin, ibuprofen and hydrocortisone on peripheral blood lymphocytes from 
healthy donors. Bulk and nano-formulations were investigated to determine if a 
reduction in particle size was accompanied by an increase in genetic toxicity. 
Results are described as OTM and percentage of tail DNA.  
The results from the OTM (figure 4-1), indicated an overall increase in genetic 
toxicity in the treated samples when compared to the negative control however, 
only the Asp B and Ibu B were significant (p = 0.0428 and 0.0178, respectively) 
(table 4-1). In each drug tested, the genotoxicity of the nano formulation was 
less than that of the bulk compound. The greatest reduction in genotoxicity from 
the bulk to nano form was seen in aspirin with an OTM of 1.53 seen in the bulk 
experiment and 1.09 in the nano form, which is only marginally higher than that 
of the negative control (1.00). Although not significant, the reduction of DNA 
damage seen in hydrocortisone from the bulk compound to the nano form was 
less than that of aspirin and ibuprofen, indicating that the reduction in particle 
size for hydrocortisone did not have as much effect as the other two drugs.  
Ibuprofen was the most genotoxic agent, with both the bulk and nano forms 
OTM exceeding that of the other compounds. A similar trend was seen in the 
percentage of DNA in the tail (figure 4-2) with a significant increase seen in 
AspB (p < 0.05), IbuB (p < 0.05) however, a significant increase in tail DNA was 
also seen in HC B (p < 0.05) (table 4-1) which was not seen in the OTM.  
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Figure 4-1 Effect of aspirin, ibuprofen and hydrocortisone bulk and nano preparations on 
lymphocytes from healthy donors using Olive Tail Moment in the comet assay.  
* indicates a significance of p < 0.05. Errors bars represent SEM.  
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Figure 4-2 Effect of aspirin, ibuprofen and hydrocortisone bulk and nano preparations on 
lymphocytes from healthy donors using % Tail DNA in the comet assay.  
* indicates a significance of p < 0.05. Errors bars represent SEM. 
 
 
Table 4-1 Olive Tail Moment and Percentage Tail DNA in Healthy Donors 
Treatment  Olive Tail Moment 
Mean ± SEM 
p value  % Tail DNA  
Mean ± SEM 
p value 
Negative Control (NC) 1.0 ± 0.1 - 7.64 ± 0.28 - 
Positive Control (PC) 1.86 ± 0.19 < 0.05 10.76 ± 0.44 < 0.05 
Aspirin Bulk (ASP B) 1.53 ± 0.17 < 0.05 9.49 ± 0.45 < 0. 05 
Aspirin Nano (ASP N) 1.09 ± 0.1 ns 8.03 ± 0.29 ns 
Ibuprofen Bulk (Ibu B) 1.81 ± 0.23 < 0.05 10.7 ± 0.49 < 0.05 
Ibubrofen Nano (Ibu N)  1.45 ± 0.18 ns 9.45 ± 0.58 ns 
Hydrocortisone Bulk (HCB) 1.30 ± 0.15 ns 9.660 ± 0.56 < 0.05 
Hydrocortisone Nano (HCN) 1.16 ± 0.11 ns 8.48 ± 0.51 ns  
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4.4.2 Genotoxicity of aspirin, ibuprofen and hydrocortisone (bulk and nano 
particles) on peripheral blood lymphocytes from patients with 
haematological cancers.  
The main target of testing these nanotised drugs is to evaluate their genotoxic 
profile and determine their potential as a cancer treatment option. Previous 
studies in our laboratory have looked at peripheral lymphocytes from patients 
with a number of different cancers including lung, prostate and breast cancer 
however these experiments have not been conducted on cancerous tissue. In 
this study, we used lymphocytes from haematological cancer patients in order 
to assess the genotoxicity of these compounds on cancerous cells. The DNA of 
cancer patients is inherently unstable and therefore their DNA is more 
susceptible to DNA damaging agents.  
Results from the OTM from haematological cancer patients (figure 4-3) showed 
a significant increase in genetic toxicity of Asp B (p < 0.05) and Ibu B (p < 0.05), 
with Ibu B being the most genotoxic agent. In both aspirin and ibuprofen, the 
nano formulations exhibited reduced genotoxicity when compared to the bulk 
counterpart, with both nano formulations being marginally increased when 
compared to the negative control. Interestingly, the HC B showed reduced 
genotoxicity when compared to the negative control (OTM 1.37 and 1.39 
respectively), however this was not significant. The HC N formulation closely 
matched the HC B, being fractionally higher with an OTM value of 1.42. Results 
from the percentage of tail DNA (figure 4-4) were similar in that Asp B and Ibu B 
demonstrated a significant increase in genotoxicity when compared to the 
negative control (p < 0.05 each) with reduced amounts of DNA damage seen in 
nano forms when compared to bulk. In contrast to OTM results, HCB 
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demonstrated marginally increased levels of DNA damage when compared to 
the negative control (8.85 % and 8.43% respectively, table 4-2).     
 
Figure 4-3 Effect of aspirin, ibuprofen and hydrocortisone bulk and nano preparations on 
lymphocytes from haematological cancer patients using Olive Tail Moment in the comet assay.  
 * indicates a significance of p < 0.05. Errors bars represent SEM. 
 
Figure 4-4 Effect of aspirin, ibuprofen and hydrocortisone bulk and nano preparations on 
lymphocytes from haematological cancer patients using % Tail DNA in the comet assay.  
* indicates a significance of p < 0.05. Errors bars represent SEM. 
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Table 4-2 Olive Tail Moment and Percentage Tail DNA in Haematological 
Cancer Patients 
Treatment  Olive Tail Moment 
Mean ± SEM 
p value  % Tail DNA  
Mean ± SEM 
p value 
Negative Control (NC) 1.39 ± 0.1 - 8.43 ± 0.28 - 
Positive Control (PC) 2.55 ± 0.17 < 0.05 12.34 ± 0.42 < 0.05 
Aspirin Bulk (ASP B) 1.95 ± 0.13 < 0.05 10.85 ± 0.42 < 0.05 
Aspirin Nano (ASP N) 1.47 ± 0.15 ns 8.86 ± 0.46 ns 
Ibuprofen Bulk (Ibu B) 1.98 ± 0.15 < 0.05 11.25 ± 0.43 < 0.05 
Ibubrofen Nano (Ibu N)  1.51 ± 0.11 ns 9.21 ± 0.45 ns 
Hydrocortisone Bulk (HCB) 1.37 ± 0.11 ns 8.85 ± 0.36 ns 
Hydrocortisone Nano (HCN) 1.42 ± 0.12 ns 8.94 ± 0.45 ns  
 
 
4.5 Discussion 
 The comet assay is considered a standard method of evaluating DNA damage 
and repair in individual cells, being easily performed on various tissue types and 
relatively inexpensive. It is highly sensitive and therefore is capable of detecting 
low levels of DNA damage including strand breaks, alkali-labile sites and DNA-
DNA/DNA-protein crosslinks. DNA damage and defective repair mechanisms 
are hallmarks of cancer and therefore the comet assay has the potential to 
investigate the characteristics of a wide range of cancerous cells in response to 
DNA damaging agents however, Frötschl (2015) highlighted the limitations of 
the in vitro comet assay as results may not be applicable to in vivo conditions. 
Previous results from our laboratory (unpublished), indicated that the nano 
versions of aspirin and ibuprofen induced less DNA damage than their bulk 
counterparts, with aspirin nanoparticles causing reduced migration when 
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compared to the negative control in PBL of healthy individuals and patients with 
breast, lung and prostate cancer. It was hypothesised that aspirin nanoparticles 
conferred a geno-protective effect. We therefore set out to determine the effects 
of these drugs, as well as hydrocortisone, on actual cancer cells and therefore 
used the PBL of patients with haematological cancer.  
In both the healthy control group and the cancer patient group, a significant 
increase in DNA damage was observed for the bulk compounds of aspirin and 
ibuprofen, with hydrocortisone bulk also showing increased levels of DNA 
damage only in the healthy control group. In each instance, the nano 
formulations of the drugs did not induce a significant increase in DNA damage. 
The results for aspirin were somewhat surprising as they did not agree with 
previous studies in our laboratory or with studies demonstrating the protective 
effect of aspirin. Aspirin has been shown to confer a geno-protective effect 
when co-administered with a known genotoxic agent. Obrecht-Pflumio et al. 
(1996) demonstrated that administration of aspirin to mice before treatment with 
the carcinogen Ochratoxin A dramatically reduced the amount of DNA adducts 
seen in the urinary bladder and kidney. A similar effect was seen when aspirin 
was co-administered with Mitomycin C (MMC) in the somatic mutation and 
recombination test (SMART) and the DNA repair assay in Drosophila 
melanogaster (Niikawa et al., 2006, Niikawa and Nagase, 2007).  
Ibuprofen bulk induced the highest levels of DNA damage in the comet assay; 
however the nano formulation did not result in a significant increase. This is in 
agreement with other studies revealing the genotoxic potential of this 
formulation in chromosomal aberration assays and micronucleus assays 
(Tripathi et al., 2012, Ragugnetti et al., 2011), these results however were in 
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contrast with findings from Philipose et al. (1997) who noted a weakly, but not 
significant, genotoxic effect in the sister chromatid exchange (SCE) in the bone 
marrow of mice and no mutagenic effects in the Ames test.  
In the healthy control population, the treatment with hydrocortisone bulk 
resulted in a significant increase in DNA damage, however this was not seen in 
the cancer patient group. This was surprising as the due to the instability of the 
DNA of cancer patients, it was predicted that the DNA of cancer patients would 
be more sensitive to genotoxic agents. More surprisingly was the apparent 
geno-protective effect seen with hydrocortisone nanoparticles on the PBL of the 
patients with cancer. The genotoxicity of hydrocortisone has been previously 
demonstrated (Bali et al., 1990) using micronuclei and sister chromatid 
exchange analyses with human PBL and mouse bone marrow studies. This 
clear clastogenic effect was not seen in this experiment. A possible explanation 
could be due to the single dose of hydrocortisone used and the short incubation 
time (30 minutes). According to Fahmy et al. (2015), a single dose of 
hydrocortisone did not have an effect on chromosomal aberrations, however, 
repeated dosing showed a significant increase in the frequency of sister 
chromatid exchanges in a dose-dependent manner, in the bone marrow of 
mice. Another explanation could be the result of DNA cross-linking during the 
comet assay. DNA-crosslinking is normally suspected when there is reduced 
migration of DNA when compared to the negative control. This was seen, only 
marginally, in the presence of hydrocortisone nano. The possibility of DNA 
cross linking in the experiments involving hydrocortisone will need to be 
investigated to fully interpret the results. This could be done according to Tice et 
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al. (2000) and Pfuhler and Wolf (1996) involving the addition of a known 
genotoxic agent and comparing the migration to that without the agent.  
Although the haematological cancer patient group demonstrated slightly higher 
levels of DNA damage in both the olive tail moment and percentage DNA in the 
tail when compared to healthy individuals, this was not as considerable as we 
expected. It has been well established that the basal levels of DNA damage in 
patients with cancer are significantly higher than healthy individuals and it is 
based on this finding that many cancer monitoring and indeed diagnostic tests 
are being conducted (McKenna et al., 2008, Anderson et al., 2014). 
Inappropriate storage and thaw time could be responsible for these findings. 
During our assays, we also discovered that the voltage during electrophoresis 
was not being maintained throughout the tank, which could have adversely 
affected the migration of DNA.  
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Effect of hydrocortisone in a highly oxidising environment in the 
comet assay 
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5 Effect of hydrocortisone in a highly oxidising environment 
in the comet assay 
5.1  Introduction  
5.1.1 Reactive Oxygen Species 
Reactive oxygen species (ROS) are highly reactive molecules generated by the 
partial reduction of oxygen and include the superoxide anion (O2
-), hydrogen 
peroxide (H2O2) and the hydroxyl radical (HO·). They are produced 
endogenously during mitochondrial oxidative phosphorylation as a by-product of 
cellular respiration, and may also be introduced exogenously through 
xenobiotics. When ROS manage to overwhelm the antioxidant mechanisms of 
the cell, either through an increase in ROS levels or a decrease in antioxidant 
capacity, oxidative stress occurs. This altered redox status leads to the 
damage, either direct or indirect, of lipids, proteins and nucleic acids and has 
been implicated in carcinogenesis (Trachootham et al., 2009), with advanced 
stage tumours exhibiting multiple genetic mutations and high levels of ROS. 
Increased levels of ROS have also been associated with an increase in tumour 
metastasis through gene activation, with ROS scavengers leading to a 
decrease in metastatic potential in tumours in mice (Ishikawa et al., 2008). ROS 
are able to modify proteins through the redox regulation of reactive cysteine 
residues leading to a change in structure and subsequently, function. ROS also 
have a role in cellular signalling and influence processes such as proliferation, 
differentiation, inflammation and cell survival through multiple ROS-sensitive 
signalling pathways, maintaining the cancerous phenotype of the cell (Ray et 
al., 2012, Storz, 2005). Elevated levels of ROS are also associated with DNA 
damage leading to lesions in the genome, contributing to cancer initiation, 
maintenance and progression. Maintaining the balance between antioxidant 
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systems and ROS generation is vital in cancer treatment and prevention; 
therefore it is of great importance to assess the antioxidant potential of drugs.   
5.2 Experimental aim 
In this experiment, we looked at the antioxidant potential of hydrocortisone in its 
bulk and nano form to establish if the two formulations of the drug were able to 
reduce the effects of a highly oxidising environment, in the comet assay.  
5.3 Materials and Methods  
All chemical used in the comet assay are listed in Table 2.1. Methods are as 
described in section 2.3 and 2.7. To test the effect of hydrocortisone in a highly 
oxidising environment, 50 µg/ml of hydrocortisone (both bulk and nano) were 
co-treated with 50µM hydrogen peroxide. Hydrogen peroxide is a potent oxygen 
radical and served to generate oxidative stress in this experiment.  
5.4 Results  
In this assay, samples were co-treated with 50µM hydrogen peroxide to assess 
the effect of hydrocortisone (bulk and nano) in the presence of a highly oxidising 
environment. As this was the same concentration of hydrogen peroxide as that 
used in the positive control, the results were compared to this positive control as 
this reflects the highly oxidising environment without the additional treatment.  
5.4.1 Effect of hydrocortisone in a highly oxidising environment in healthy 
donors  
The presence of hydrocortisone nano particles significantly reduced the effects 
of the hydrogen peroxide when compared to the positive control in both the 
OTM (1.32) and percentage tail DNA (8.80%) (p < 0.05) (Figures 5-1, 5-2 and 
table 5-1). A reduction in hydrogen peroxide effects were also seen in the bulk 
53 
 
compound, however, these were not significant. Interestingly, both results for 
HC N were not significantly different from the negative control. 
   
 
Figure 5-1 Effect of hydrocortisone in a highly oxidising environment in healthy donors using Olive 
Tail Moment in the comet assay. 
 * indicates a significance of p < 0.05. Errors bars represent SEM. 
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Figure 5-2 Effect of hydrocortisone in a highly oxidising environment in healthy donors using % 
Tail DNA in the comet assay.   
* indicates a significance of p < 0.05. Errors bars represent SEM. 
  
Table 5-1 Olive Tail Moment and Percentage Tail DNA of healthy donors 
Treatment  Olive Tail Moment 
Mean ± SEM 
p value  % Tail DNA  
Mean ± SEM 
p value 
Negative Control (NC) 1.0 ± 0.1 - 7.64 ± 0.28 - 
Positive Control (PC) 1.86 ± 0.19 - 10.76 ± 0.44 - 
Hydrogen Peroxide + 
Hydrocortisone Bulk 
(HPHCB) 
1.53 ± 0.18 ns 9.64 ± 0.51 ns 
Hydrogen Peroxide + 
Hydrocortisone Nano 
(HPHCN) 
1.32 ± 0.15 < 0.05 8.79 ± 0.55 < 0.05 
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5.4.2 Effect of hydrocortisone in a highly oxidising environment in 
haematological cancer patients  
In lymphocytes from patients with haematological cancers, the presence of 
hydrocortisone bulk and nano particles significantly reduced the effects of the 
hydrogen peroxide when compared to the positive control (figures 5-3, 5-4 and 
table 5-2). An OTM result of HC B was marginally higher than that obtained for 
HC N, with a similar trend seen in the percentage of tail DNA. As seen in the 
healthy donors, the HC N (OTM and % Tail DNA) were not significantly different 
from the negative control. The HC B OTM result was also not significantly 
different from the negative control.    
 
 
Figure 5-3 Effect of hydrocortisone in a highly oxidising environment in haematological cancer 
patients using Olive Tail Moment in the comet assay.  
* indicates a significance of p < 0.05. Errors bars represent SEM. 
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Figure 5-4 Effect of hydrocortisone in a highly oxidising environment in haematological cancer 
patients using % Tail DNA in the comet assay. 
 * indicates a significance of p < 0.05. Errors bars represent SEM. 
 
Table 5-2 Olive Tail Moment and Percentage Tail DNA of haematological cancer patients 
Treatment  Olive Tail Moment 
Mean ± SEM 
p value  % Tail DNA  
Mean ± SEM 
p value 
Negative Control (NC) 1.39 ± 0.1 - 8.43 ± 0.28 - 
Positive Control (PC) 2.55 ± 0.17 - 12.34 ± 0.42 - 
Hydrogen Peroxide + 
Hydrocortisone Bulk 
(HPHCB) 
1.70 ± 0.14 < 0.05 10.30 ± 0.46 < 0.05 
Hydrocortisone Nano 
(HPHCN) 
1.55 ± 0.13 < 0.05 9.71 ± 0.48 < 0.05 
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5.5 Discussion 
Oxidative stress occurs when the amount of reactive oxygen species exceeds 
the antioxidant capacity of the cell, leading to a number of clinical conditions, 
including cancer (Auten and Davis, 2009). Lee et al. (2013) showed that 
hydrocortisone had antioxidant effects during ischemia and reperfusion and 
therefore we set out to determine whether hydrocortisone (bulk and nano 
particles) displayed antioxidant effects in PBL in the presence of H2O2. In our 
previous experiments involving hydrocortisone nanoparticles, the reduction in 
particle size was not accompanied by an increase in DNA damage (see chapter 
4), however the association between ROS generation and nanoparticle toxicity 
is well documented (Fu et al., 2014) and therefore we wanted to determine 
whether hydrocortisone nanoparticles would exacerbate an oxidising 
environment or alternatively alleviate some of the DNA damage generated by 
ROS .  
The comet assay has previously been used to determine antioxidant properties 
of various agents in a highly oxidising environment (Anderson et al., 1994). In 
PBL of both study groups, healthy donors and haematological cancer patients, 
the presence of hydrocortisone in the highly oxidising environment induced by 
H2O2 treatment resulted in a reduced incidence of DNA damage when 
compared to controls in the absence of hydrocortisone. The nano version of 
hydrocortisone had the greatest effect, with results not significantly different 
from that of the negative control that was not treated with H2O2. This indicates 
that the presence of hydrocortisone could potentially act as a direct antioxidant 
or is able to influence the generation and capacity of endogenous antioxidant 
systems. G. Sandal (2013) demonstrated a similar finding when looking at the 
58 
 
influence of hydrocortisone on the antioxidant system in preterm infants with 
bronchopulmonary dysplasia. They found a significant decrease in the total 
oxidant status (TOS) and oxidative stress index (OSI) with an increase in total 
antioxidant capacity (TAC) after treatment with hydrocortisone.  
 The oxidative effects of H2O2 are as a result of its spontaneous conversion to 
the highly reactive hydroxyl radical (OH·), catalysed by Fe2+ in the Fenton 
reaction (Winterbourn, 1995). Another possibility of the effects of hydrocortisone 
seen here could be an interference with this Fenton reaction, resulting in 
reduced levels of the hydroxyl radical being produced. Another possibility is the 
effect of hydrocortisone on the expression of inflammatory mediators. Reuter et 
al. (2010) reviewed the relationship between inflammation, oxidative stress and 
cancer risk, illustrating that they are closely liked.  
Oxidative stress is a clear link between environmental toxicity and 
carcinogenesis. Oxidative lesions resulting from the direct and indirect effects of 
free radicals have been implicated in the aetiology of cancer (Fuchs-Tarlovsky, 
2013). Increased levels of oxidative stress markers and decreased levels of 
antioxidants seen in different types of cancer highlight the important role ROS 
play in the pathophysiology of cancer (Badjatia et al., Sharma et al., 2009, 
Klarod et al., 2011). To mitigate the effects of elevated levels of ROS in cancer 
development and treatment, the use of antioxidants gained much interest. A 
number of randomised controlled studies however, were unable to provide 
evidence that antioxidant supplementation was beneficial in primary cancer 
prevention (National Cancer Institute, 2014). Studies looking at the use of 
antioxidants to alleviate treatment toxicities have produced contradictory results 
(Ladas et al., 2004), with concerns being raised over the ability of antioxidants 
59 
 
to alter or reduce the effectiveness of specific therapies leading to tumour 
protection and reduced survival (Lawenda et al., 2008). The different 
mechanisms of antioxidant and cancer therapy action have been implicated in 
the inconsistencies seen and therefore the combinations need to be matched to 
ensure the interaction produces a desired effect.  
As hydrocortisone is a powerful anti-inflammatory agent, the reduction in 
inflammatory signal could result in the reduction of oxidative stress. Further 
work is required in order to determine the exact mechanism of this apparent 
antioxidant effect of hydrocortisone. It would therefore also be appropriate to 
determine the effect of hydrocortisone in combination with other cancer 
therapies to further understand the interactions between the drugs.   
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nano preparations on peripheral lymphocytes in the cytokinesis 
block micronucleus assay 
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6 Genotoxic effects of aspirin, ibuprofen and hydrocortisone 
bulk and nano preparations on peripheral lymphocytes in 
the cytokinesis block micronucleus assay.  
6.1 Introduction 
6.1.1 Micronucleus assay 
The micronucleus (MNi) assay is an essential assay in genotoxicity as it 
enables chromosome mutations that are a direct consequence of DNA damage 
to be assessed which is an important event in carcinogenesis. Micronuclei are a 
product of chromosome fragments or entire chromosomes that lag behind at 
anaphase and are subsequently excluded from the nucleus.  The MNi assay 
allows both chromosome loss and breakage to be measured reliably however 
this damage can only be expressed as MNi in cells during interphase. The MNi 
frequency also declines with repeated division and therefore comparison of MNi 
frequency cannot be established between populations of dividing cells (Fenech, 
1997). This lead to a modification of the technique in which cytochalasin-B (CB) 
was added to block cytokinesis and halt cell division in the binucleated phase.  
The CBMN assay can be used to measure chromosome breakage, loss, 
rearrangement, gene amplification and excision repair. It is also used to 
determine cell division inhibition, necrosis and apoptosis (Fenech, 2006, 
Fenech et al., 2011)  The CBMN is preferred over the MNi as half the numbers 
of cells require scoring and these are restricted to cells that have divided once 
and are recognised by their binucleated (BiN) appearance. In addition to MNi 
visualisation, nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) can be 
visualised. NPBs are an indication of chromosome rearrangement and this is 
normally missed as cells proceed through anaphase and telophase rapidly 
however the inhibition of cytokinesis in CBMN allow BN cells with NPBs to 
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accumulate and be observed. These NPBs are important as they are an 
initiating event in breakage-fusion-bridge (BFB) cycles which leads to 
chromosomal instability. Nuclear buds (NBUD) are an indication of gene 
amplification. Excess amplified DNA is relocated to the periphery of the nucleus 
where it buds off as a MN linked to the nucleus by a stalk of nucleoplasmic 
material. The CBMN assay is a well-established technique however its 
efficiency is dependent on Cyt-B concentration and therefore the optimum dose 
needs to be established for each cell type to ensure cells to not escape the 
cytokinesis block (Surrallés et al., 1992).  
6.2 Materials and Methods 
All chemicals used in the CBMN assay are listed in table 2.1. Methods are as 
described in section 2.8. Whole blood was collected by venepuncture into 
lithium heparin Vacuette containers from healthy individuals and patients with 
haematological cancers and was processed on the same day as collection. 5 
samples from each healthy donors and cancer patients were used.  
6.3 Results  
At the doses for the three drugs selected, neither drug was significantly 
genotoxic when compared to the negative control, in both the healthy donors 
and haematological cancer patients; however the frequency of MNi were slightly 
raised (figure 6-1 and table 6-1). In healthy donors, the frequency of MNi was 
higher in Asp B when compared to Asp N, which supports data obtained from 
the comet assay, indicating that a decrease in particle size of aspirin is not 
associated with an increase in genotoxicity. Surprisingly, the frequency of MNi 
from cells treated with Ibu B equalled the levels obtained with Ibu N, which is in 
contrast to the trend seen in the comet assay. In each case of the comet assay, 
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the nano form of the ibuprofen showed a lower degree of genotoxicity than the 
bulk compound. HC B showed the highest increase in MNi in all drugs tested, 
with HC N showing decreased levels when compared to the bulk compound; 
however it had a higher MNi frequency than Asp and Ibu (bulk and nano). It 
should be noted that the positive control treated with mitomycin C in one of the 
healthy donors showed an abnormally high induction of MNi when compared to 
the other healthy donors. All other results were consistent. This could have 
been an error in the MMC dosing as the other treatments did not show 
increased MNi frequencies, therefore making increased susceptibility to DNA 
damaging agents unlikely. The Nuclear Division Index (NDI) for healthy donors 
ranged from 1.81-2.05 which was within normal expected limits of 1.3-2.2; 
(Fenech, 2007) with the frequency of bi-nucleated cells exceeding 50% of the 
fraction in each instance (figure 6-2). The frequency of NPBs and NBUDs were 
also within normal limits.  
In patients with haematological cancers, Asp N induced a marginally higher 
level of MNi when compared to Asp B, which was surprising as this is in 
contrast to other results obtained in healthy donors and that seen in the comet 
assay. However the MNi frequency for aspirin was considerably less than that 
seen in ibuprofen, both bulk and nano, which is consistent with data from the 
comet assay. Both Ibu B and HC B induced higher frequencies of MNi when 
compared to their nano counterpart. It is clear from figure 6-1 that the difference 
in MNi frequency is significantly increased in the haematological cancer group 
when compared to the healthy donors. The NDI for patients with haematological 
cancers ranged from 1.73 – 2.04, with the lowest NDI lower than healthy 
individuals however still within normal ranges with a frequency of BN cells of 
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over 50% (figure 6-3). The frequency of NPBs and NBUDs were marginally 
higher than that obtained for healthy individuals, especially with regard to 
NBUDs however all were within normal limits.  
 
Figure 6-1 Frequency of BiNC with MNi per 1000 cells using the CBMN Assay.  Results from healthy 
donors are in blue and haematological cancer patients in red.   
Errors bars represent SEM. 
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Figure 6-2 Proliferative status of viable cells in Healthy donors. Number of nuclei (%) per 1000 scored 
cells in the CBMN assay of BiNC (blue), monoNC (red) and multiNC (green).  
Error bars represent SEM.  
 
 
Figure 6-3 Proliferative status of viable cells in patients with haematological cancer.  Number of 
nuclei (%) per 1000 scored cells in the CBMN assay of BiNC (blue), monoNC (red) and multiNC (green).  
Error bars represent SEM.   
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Table 6-1 Micronucleus assay proliferative and genotoxic effects 
Subject 
Treatment 
Group  NDI % BiNC % MoNC % Multi-NC 
 BiNC cells 
BiMNi BiNPB BiBuds 
 
 
Healthy 
individuals 
NC 2.05 ± 0.12 51.40 ± 5.57 20.94 ± 5.31 27.40 ± 8.00 1.80 ± 1.07 0.00 ± 0.00 0.60 ± 0.40 
MMC 1.87 ± 0.05 60.74 ± 5.40 26.12 ± 2.19 23.74 ± 5.31 30.20 ± 10.23 1.40 ± 1.40 0.00 ± 0.00 
Asp - B 2.03 ± 0.10 56.60 ± 3.49 21.44 ± 3.84 24.00 ± 5.74 5.20 ± 0.80 0.20 ± 0.20 0.80 ± 0.49 
Asp - N 1.86 ± 0.06 62.00 ± 4.34 26.22 ± 3.91 12.00 ± 3.29 3.20 ± 0.37 0.20 ± 0.20 0.20 ± 0.20 
Ibu - B 1.87 ± 0.06 59.40 ± 4.31 26.88 ± 4.24 13.60 ± 3.26 5.20 ± 0.97 0.00 ± 0.00 0.60 ± 0.40 
Ibu- N 1.90 ± 0.05 57.60 ± 4.15 26.28 ± 2.75 16.20 ± 3.65 5.20 ± 1.56 0.20 ± 0.20 0.60 ± 0.40 
HC - B 1.81 ± 0.06 61.40 ± 1.72 28.82 ± 3.94 10.00 ± 2.49 7.20 ± 2.08 0.20 ± 0.20 0.40 ± 0.40 
HC - N 1.87 ± 0.07 60.00 ± 0.63 26.54 ± 3.81 13.60 ± 3.26 5.40 ± 1.40 0.20 ± 0.20 0.20 ± 0.20 
 
 
Cancer 
Patients 
NC 2.04 ± 0.08 53.20 ± 1.66 21.54 ± 4.05 25.60 ± 3.98 15.00 ± 1.76 0.60 ± 0.40 1.20 ± 0.49 
MMC 1.73 ± 0.10 56.30 ± 4.89 35.34 ± 7.09 11.42 ± 2.71 31.60 ± 2.89 2.40 ± 0.40 1.20 ± 0.37 
Asp - B 1.97 ± 0.08 56.20 ± 1.85 23.52 ± 4.55 20.20 ± 3.54 15.20 ± 1.53 0.40 ± 0.24 1.00 ± 0.45 
Asp - N 1.82 ± 0.07 61.40 ± 2.87 28.58 ± 4.84 10.20 ± 2.20 15.80 ± 1.66 0.80 ± 0.20 1.40 ± 0.51 
Ibu - B 1.86 ± 0.07 62.20 ± 3.26 26.92 ± 5.25 11.00 ± 2.28 21.60 ± 2.25 0.40 ± 0.24 1.00 ± 0.55 
Ibu - N 1.91 ± 0.08 56.80 ± 3.06 25.98 ± 5.24 17.20 ± 2.33 20.00 ± 1.05 0.60 ± 0.24 1.60 ± 0.75 
HC - B 1.78 ± 0.04 59.80 ± 2.85 30.78 ± 3.55 9.40 ± 1.03 20.20 ± 2.03 0.80 ± 0.20 0.80 ± 0.20 
HC - N 1.85 ± 0.04 63.20 ± 3.10 26.04 ± 3.39 10.80 ± 1.59 18.20 ± 1.50 0.60 ± 0.40 1.00 ± 0.32 
 
NC – Negative control, PC- positive control with mytomycin C treatment, Asp-B – aspirin bulk, Asp-N – aspirin nano, Ibu-B – ibuprofen bulk, Ibu-N – ibuprofen nano, HC-
B – hydrocortisone bulk, HC-N – hydrocortisone nano, NDI – nuclear division index, BiNC- binucleated cells, MoNC – mononucleated cells, Multi-NC – multinucleated 
cells, BiMNi – binucleated cells with micronuclei, BiNPB – binucleated cells with nucleoplasmic bridges, BiBuds – binucleated cells with nuclear buds. 
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6.4 Discussion  
 The Cytokinesis-block micronucleus assay has become an important test in the 
screening of potentially genotoxic compounds. It has the ability to detect 
clastogenic and aneugenic events in multiple cell types. The presence of 
micronuclei and other abnormalities such as nucleoplasmic bridges and nuclear 
buds are indicators of genomic instability, a hallmark of cancer. In this study, we 
looked at the genotoxicity of aspirin, ibuprofen and hydrocortisone in bulk and 
nano formulations in the CBMN assay.  The nuclear division index (NDI) is a 
marker of cell proliferation and therefore a measure of general cytotoxicity with 
a large degree of chromosomal damage resulting in a lower NDI. If all viable 
cells fail to divide, they will be mono-nucleated with a NDI score of 1.0. If all 
viable cells completed nuclear division, they will be binucleated with an NDI of 
2.0. If viable cells divide more than once and appear multi-nucleated, the NDI 
score will be above 2.0 (Fenech, 2007). In both study groups, healthy donors 
and haematological patients, the NDI of the negative control was 2.05 and 2.04 
respectively, indicating a low level of chromosome damage. The NDI for 
haematological cancer patients was surprising as a lower NDI, indicative of 
genomic instability, would have been expected. All treatments in both groups 
resulted in a decrease of the NDI; however these were all in normal limits. The 
proportion of apoptotic and necrotic cells however were not scored, limiting the 
data available to assess the cytotoxic effects of the drugs. The MNi frequency 
increased in each treatment group when compared to the negative control; 
however this increase was not significant. Aspirin in its bulk and nano form were 
the least genotoxic agents in both study groups, with hydrocortisone bulk 
inducing the highest increase in MNi frequency in healthy controls and 
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ibuprofen bulk inducing the highest increase in MNi frequency in haematological 
cancer patients. In general, the study group of patients with haematological 
cancers had a significantly higher MNi frequency when compared to healthy 
donors, in all treatment groups as well as the negative control. This was as 
expected as a higher degree of chromosome damage and genomic instability 
was expected in this group, making the PBL more susceptible to genetic insult 
giving rise to increase MNi frequencies (Fenech et al., 1999, El-Zein et al., 
2008). Repeated measures were difficult in light of only receiving one blood 
sample from the patients with haematological cancers. This experiment would 
produce more robust results if the cohort was expanded and repeated testing 
was done in addition to establishing a dose-dependent relationship for each 
drug formulation.  
These results are encouraging as this is the first time these drugs have been 
tested in their nano form directly on cancer cells. Although no geno-protective 
effect was seen, neither of the drugs induced significantly increased levels of 
chromosomal abnormalities and therefore the potential for them to be used as 
an adjuvant in cancer therapy remains plausible.  
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7 Discussion 
Mutations in DNA can result from a number of sources, including physical, 
chemical and biological means leading to genomic instability and cancer. 
Therefore it has become essential to assess genotoxicity as part of the drug 
validation process. The comet and micronucleus assays have been recognised 
as a valid test for genotoxicity by the regulatory agencies due to their sensitivity 
and high statistical power in identifying mutagenicity in the form of DNA and 
chromosomal damage. As this work is exploratory, the use of the in vitro comet 
and micronucleus assays was employed.  
The link between chronic inflammation and cancer is well established. Strong 
correlations between the presence and persistence of inflammation at a 
particular site with the development of pre-cancerous lesions exist (Nelson et 
al., 2004, Otsuki, 2003, Macarthur et al., 2004, Coussens and Werb, 2002) 
intimating that inflammation facilitates cancer development and progression. 
During chronic inflammation, pro-inflammatory mediators are upregulated, 
altering the dynamics of the local microenvironment that promotes the 
development of cancer through multiple events including increased incidence of 
DNA damage, increased cellular proliferation and inhibition of apoptosis 
(Hofseth and Ying, 2006). Due to the numerous pro-tumour effects generated 
by the presence of inflammation, it has become a key target in cancer treatment 
and prevention. This report looked at three well known anti-inflammatory drugs, 
two NSAIDs and one corticosteroid, and their effect on DNA damage in 
peripheral blood lymphocytes in healthy donors and patients with a variety of 
different haematological malignancies to determine whether they had geno-
protective or genotoxic effects in individual cells.  
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NSAIDs inhibit COX enzyme activity which reduces the effects of inflammation. 
It has therefore become a key drug class in the effort to find agents to improve 
the outcome of certain cancerous states as well as being a preventative 
measure. A number of studies have demonstrated the potential for aspirin in the 
prevention of cancer with associations of reduced metastasis, reduced 
incidence and a reduction in mortality in colorectal cancer, adenocarcinoma, 
lung, prostate, pancreatic, breast and oesophageal cancer (Flossmann and 
Rothwell, 2007, Rothwell et al., 2011, Rothwell et al., 2010b, Rothwell et al., 
2012, Streicher et al., 2014, Bosetti et al., 2012). Evidence also suggests that 
aspirin may have geno-protective action, with treatment leading to an increase 
in DNA repair mechanisms (Dibra et al., 2010). These studies however conflict 
with reports showing no association between aspirin use and the reduced 
incidence in cancer (Sturmer et al., 1998, Cook et al., 2005) and an association 
between increased breast cancer incidence and aspirin use (Friis et al., 2008). 
Our results, in both the comet assay and the micronucleus assay, did not find a 
geno-protective effect for aspirin. These results do not agree with other data 
generated in our laboratory (Najafzadeh et al., 2016) in which aspirin exhibited 
anti-cancer effects in lung cancer. In this study, however, it was the first time 
these compounds had been tested directly on cancerous cells and therefore 
variations were to be expected. Ibuprofen was clearly the most genotoxic of the 
two NSAIDs, with higher rates of DNA damage and MNi induction. This is in 
agreement with finding from Tripathi et al. (2012) and Ragugnetti et al. (2011) 
who demonstrated increased chromosomal aberrations in mouse bone marrow 
and increased MNi frequency in Oreochromis niloticus fish, respectively.   
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Although results here are different, there is overwhelming evidence that NSAIDs 
have potential in the treatment of cancer. In their current form, aspirin and 
ibuprofen both have limitations in their bioavailability. Aspirin is a class III drug 
and therefore absorption is the limiting step. Ibuprofen, a class II drug, is only 
slightly soluble in water and therefore the bioavailability is limited by its 
dissolution rate. In order to increase the bioavailability of these drugs, nano 
forms are being produced. Our results when comparing the nano forms of the 
drugs to their bulk forms demonstrate that a decrease in particle size 
corresponds to a difference in response. In each case, the nano form of the 
drug was less genotoxic than its bulk counterpart, often not significantly different 
from the untreated control. This highlights the potential of these drugs in their 
nano form to be used as therapeutic options, however more testing needs to be 
done before conclusions can be confidently drawn.  
Another anti-inflammatory drug examined was the glucocorticoid 
hydrocortisone. Hydrocortisone has been used in a co-treatment regime in 
many haematological malignancies due to its anti-inflammatory and anti-cancer 
effects. These effects are due to the regulation of the glucocorticoid receptor 
which reduces the expression of pro-inflammatory genes, negatively regulates 
survival cytokines and induces the expression of pro-apoptotic genes, leading to 
a suppression of tumour progression and metastasis (Lin and Wang, 2016). 
Yano et al. (2006) found that the glucocorticoids dexamethasone and 
hydrocortisone supressed androgen-independent prostate cancer growth 
through the inhibition of tumour-associated angiogenesis. 
In our studies of the genotoxicity of hydrocortisone in the comet assay, 
treatment of PBL with hydrocortisone in both the bulk and nano form did not 
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induce a significant increase in DNA damage in both study groups, with 
hydrocortisone treatment in the haematological cancer patient group very 
similar to the untreated control. The genotoxicity of hydrocortisone seen in the 
micronucleus assay however was higher than that seen in the comet assay, 
however the induction of MNi was not significant. This is in contrast to the 
studies by Fahmy et al. (2015), Fahmy (2014) who demonstrated the dose-
dependent increase in chromosomal aberrations and sister chromatid 
exchanges after multiple does of hydrocortisone. They did however find that a 
single treatment of hydrocortisone at different doses did not induce genotoxicity 
(Fahmy et al., 2015) which could explain the lack of toxicity found in this work. 
Although the nano version of hydrocortisone induced less DNA damage than 
that of its bulk counterpart, especially in anti-oxidant assays, this difference in 
action of the two formulations was not as profound as that of aspirin and 
ibuprofen, demonstrating that the reduction in particle size of hydrocortisone did 
not generate a significantly different response from the bulk form. Our results 
also demonstrated, at this particular dose, the potential of hydrocortisone as an 
antioxidant with hydrogen peroxide-induced oxidative stress reduced in co-
treatment experiments. A study by Alotaibi et al. (2013) demonstrated that 
polyphenol compounds can act as both antioxidants and pro-oxidants, 
depending on the form and dose of administration. It is therefore reasonable to 
conduct further experiments to determine if hydrocortisone (in either bulk or 
nano) could act in a similar manner.  
Human lymphocytes were chosen to assess genomic sensitivity to potential 
genotoxins in the alkaline Comet assay and the Micronucleus assay. Peripheral 
blood lymphocytes are regarded as suitable cells in biomonitoring experiments 
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(Albertini et al., 2000) as large populations circulate through the entire body, 
being exposed to different microenvironments including genetic insults 
(Anderson et al., 2014). The effect of long term cryo-storage on whole blood is 
said to maintain the viability of cells for up to ten years (Abbruzzese et al., 
2013). The effects of cryopreservation on isolated lymphocytes is conflicting 
with Duthie et al. (2002) reporting that cryopreservation had no detrimental 
effect on endogenous or induced mutation frequencies in human lymphocytes 
however the cryopreserved lymphocytes were defective in repair assays when 
compared to fresh lymphocytes.  Fang et al. (2015) however noted that 
lymphocytes cryopreserved prior to lysis and electrophoresis exhibited 
significantly increased frequencies of single-strand breaks when compared to 
fresh lymphocytes. Another factor to be considered is the use of whole blood 
instead of isolated lymphocytes. Studies indicate that the presence of whole 
blood induced significant increases in DNA damage in lymphocytes in the 
comet assay and that DNA damage was elevated 10-fold in lymphocytes 
analysed in the presence of red blood cells (RBC) compared with isolated 
lymphocytes (Narayanan et al., 2001). Components in whole blood, including 
lysis of RBC and activated neutrophils, are capable of causing increased 
incidence of DNA strand breaks through the release of haemoglobin and ROS 
generation. This is further supported by Chuang and Hu (2004) who described 
the inability to use whole blood for in vitro work due to the interference from 
RBC and recommended RBC lysis and separation by centrifugation prior to use 
if lymphocytes could not be isolated. The method used in this study involves the 
use of DMSO as a cryo-preservative and iron chelator, protecting the sample 
viability from RBC lysis. This method of using whole blood instead of isolated 
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lymphocytes demonstrated no significant difference between the two methods, 
with the former being a more rapid method requiring a smaller blood volume 
(Najafzadeh and Anderson, 2016).   
Conclusion  
Anti-inflammatory medications have great potential to be used as adjuvants and 
in combination therapy in cancer treatment and represent a novel, less toxic 
treatment option. Current use of these agents has been restricted by their side 
effects; however we have demonstrated increased activity when the particle 
size is decreased to the nano scale. This offers increased reactivity and 
bioavailability, without increased genetic toxicity during in vitro assays on 
human PBL.  
8 Study limitations 
There were many confounding factors between the healthy control group and 
the haematological cancer patient group which made comparisons between 
these groups difficult. Many of the samples from the healthy donors group had 
been previously collected and stored with details released after completion of 
the study. Some of these details were very limited as questionnaires were not 
filled out with as much detail as those in the haematological cancer group. As 
volunteers were recruited from the university campus, bias was introduced in 
terms of age and ethnicity. Samples from the haematological cancer group had 
a great degree of bias with majority of patients recruited from the same ethnic 
background and generally from the older population. In light of these 
confounding factors, results were compared within a group and not between 
groups.  
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9 Future work 
Further work in this study would initially involve recruitment of a healthy control 
group that would enable comparisons to be made between the healthy control 
group and the haematological cancer group. A broader range of glucocorticoid 
drugs would be analysed to further investigate the anti-oxidant effects of these 
drugs in cancer patients. It would be interesting to compare the short acting 
hydrocortisone to the intermediate acting triamcinolone and the long acting 
glucocorticoid dexamethasone, which both have superior anti-inflammatory 
effects with reduced mineral-corticoid effects when compared to hydrocortisone. 
The Comet Repair assay would be performed on all proposed and previously 
used drugs in this study to determine the effect of treatment on DNA repair 
mechanisms in healthy and cancer patients. Performing qPCR using human cell 
cycle PCR arrays would also enable us to identify the expression profiles of 
genes involved in positively and negatively regulating the cell cycle.  
A more detailed look at the structure of the different nanoparticles using SEM 
would help in understanding the interactions of nanoparticles with host cells. 
Further to this, TEM could be used to investigate nano particle entry into cells 
and cell localisation.  
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Appendix 1 : Abbreviations  
 
AP1: activating protein 1  
ASP B: Aspirin bulk 
ASP N: Aspirin nano 
AuNPs: gold nanoparticles 
CBMN: Cytokinesis-Block Micronucleus assay  
CuO: copper oxide 
COX-1: Cyclooxygenase enzyme 1 
COX-2: Cyclooxygenase enzyme 2 
DUSP1: Dual specificity phosphatase 1 
IBU B: Ibuprofen bulk 
IBU N: Ibuprofen nano 
MMC: Mitomycin C 
NSAIDS: Non-steroidal anti-inflammatory drugs 
DSB: DNA double strand break 
EDTA: Ethylene diamine tetrachloro acetic acid 
FBS: Foetal bovine serum 
GC: Glucocorticoid  
GR: Glucocorticoid receptor  
GSH: Glutathione  
H2O2 : Hydrogen peroxide 
HC: hydrocortisone  
HC B: hydrocortisone bulk  
HC N: hydrocortisone nano 
HO: Hydroxyl radical 
LMP: Low melting point agarose 
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MN: Micronucleus 
NAC: N-acetylcysteine 
NaCl: Sodium chloride 
NaOH: Sodium hydroxide 
NC: Negative control 
NDI: The nuclear division index 
NF-kB: nuclear factor kappaB  
NMP: Normal melting point agarose 
NPs: Nanoparticles 
NSAID: Nonsteroidal anti-inflammatory drugs 
NAG-1: NSAID-induced gene  
OS: Oxidative stress  
PBL: Peripheral blood lymphocytes  
PC: positive control 
PG: Prostaglandin 
PHA: Phytohaemagglutinin 
RNS: Reactive nitrogen species 
ROS: Reactive oxygen species 
SEM: Standard error of the mean  
SGCE: Single cell gel electrophoresis 
S1-P: sphingosine-1-phosphate  
SSB: single strand break 
TiO2: Titanium oxide  
 µM: Micro molar 
ZnO: Zinc oxide  
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Appendix 2 : Population Characteristics  
Population characteristics of healthy donors  
Sample  Gender Age Ethnicity Smoking History  Cigarettes per 
day 
1 M 42 Asian Non-smoker - 
2 M 63 White Other Non-smoker - 
3 F  Arab Non-smoker -  
4 M 32 - Non-smoker - 
5 M 36 Arab Smoker 15 
6 F 23 White British Non-smoker - 
7 F 23 White Other Non-smoker - 
8 M 18 White British Non-smoker - 
9 F 40 Asian Non-smoker - 
10 M 29 Black African Non-smoker - 
11 M 27 White British Past smoker 3 
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Population characteristics of haematological cancer patients  
Sample  Gender Age Ethnicity Smoking History Cigarettes 
per day 
Cancer diagnosis  Other medical 
conditions  
Prescribed drug use / 
other medication  
1 F 55 White British Past Smoker 30 Follicular lymphoma Previous breast 
cancer  
Anastrozole 
2 F 62 White British Non-smoker - Marginal  zone  
lymphoma 
Fibromyalgia, 
COPD 
Amitriptyline, tramadol, 
cetirizine, seretide, ventalin, 
setraile, ,  
3 M 74 White British Past Smoker 12 Systemic marginal 
zone lymphoma  
None Blood pressure tablets  
Vitamin C  
4 M 50 White British Past Smoker 10 Extranodal marginal 
zone lymphoma 
Previous testicular 
cancer  
None 
5 M 66 White British Non-smoker - Follicular lymphoma Rosacea, 
psoriasis  
Oxytetracycline, acitretin , 
cod liver oil 
6 F 54 White British Smoker 20 Mantle cell lymphoma Ulcerative colitis Atorvastatin, 
bendroflumethiazide, 
doxazosin, ramipril 
7 F 85 White British Smoker 2 IgG MGUS COPD, T2 
diabetic, ischemic 
heart disease, 
polymyalgia 
Budesonide, formoterol, 
Glyceryl trinitrate, 
omeprazole, simvastatin, 
calcichew, aspirin, 
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rheumatica paracetamol, tiotropium 
bromide, atenolol, movicol, 
alendronic acid  
8 M 89 White British Past Smoker -  Marginal zone 
lymphoma  
diverticular 
disease 
Lansoprazole, 
bendroflumethiazide, aspirin, 
amlodipine 
9 M 81 White British Past Smoker 20 Melanoma and  
chronic lymphocytic 
leukaemia 
None Fish oil 
 
10 M 64 White British Smoker 12 Marginal zone 
lymphoma 
Chronic heart 
failure 
Bisoprolol, forceval, Ramipril, 
bumetamide, lansoprazole, 
spirolactone, folic acid, 
quetiapine, thiamine, vit B 
11 F 77 White British Non-smoker - Follicular lymphoma None None 
12 M 50 White British Non-smoker - Follicular lymphoma eczema Flucoxicillin 
13 M 81 White British Past Smoker 10 Follicular lymphoma 
/composite lymphoma 
Heart block - 
pacemaker, 
hypertension, 
asthma, impaired 
glucose tolerance 
ramipril, aspirin, doxazosin, 
salbutamol spray, felodipine, 
pravastatin, adcal 
14 F 63 White British Past Smoker 20 Marginal zone Osteoarthritis, Ramipril, simvastatin 
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lymphoma type 2 diabetes, 
chronic kidney 
disease stage 3/4 
15 F 69 White British Past Smoker 2 Follicular lymphoma None None 
16 M 79 White British Past Smoker 3 Marginal zone 
lymphoma, prostate 
cancer 
None Sodium alginate, potassium 
bicarbonate, tamsulosin, 
warfarin, felodipine, 
nitrofurantoin, sildenafril 
17 F 83 White British Non-smoker - Follicular lymphoma None None 
18 M 78 White British Past Smoker 25-30 Systemic marginal 
zone lymphoma 
demyelinating 
neuropathy, IgM 
paraprotein 
Adcal d3, alendronic acid 
19 M 66 White British Non-smoker - Pre-cancerous CD5 
+ve, CD25 –ve 
lymphoproliferative 
disorder 
Chronic kidney 
disease, 
hypertension  
Amlodipine, Lisinopril, 
atorrastatin, clopidogrel 
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Appendix 3 – Consent form  
 
 School of Life Sciences 
  
 
Centre Number:  
 
 
CONSENT FORM  
 
 
Title of Project: Genetic and environmental effects in lymphocytes from different cancerous, 
precancerous and inflammatory conditions using various genetic endpoints 
 
Reviewed by Leeds East Research Ethics Committee (REC) 
 (REC reference number:  12/YH/0464       )  
 
 
Names of Researchers: Prof. D Anderson, Dr. Mojgan Najafzadeh,  Mr M Salhab 
 Please tick  
       box  
 
1. I confirm that I have read and understand the information sheet (version  ) for the above 
study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the NHS Trust or the University of 
Bradford, where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to my records.  
 
4. I agree that the sample I have given and the information gathered about me can be 
stored at the University of Bradford, as described in the attached information sheet. 
 
 
5. I agree to take part in the above study. 
 
 
 
 
___________________________ ___________________  
 Patient number Date   
 
 
 
___________________________ ___________________ _______________________ 
Name of Person  Date  Signature  
taking consent  
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes 
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Appendix 4 – Data collection form 
 
 School of Life Sciences 
  
                                DATA COLLECTION FORM 
STUDY TITLE: Genetic and environmental effects in lymphocytes from different cancerous, 
precancerous and inflammatory conditions using various genetic endpoints 
REVIEWED BY LEEDS East RESEARCH ETHICS COMMITTEE (REC)   
 (REC REFERENCE NUMBER: 12/YH/0464 )    
                    
PATIENT NUMBER   DATE OF SAMPLE  
     
AGE       
     
SEX (PLEASE TICK) M F  CONSENT    Y / N  
ETHNIC GROUP   INFORMATION SHEET Y / N  
 
OCCUPATION  
 
 
DIET WESTERN ASIAN OMNIVORE VEGETARIAN VEGAN 
 
VITAMINS / ANTI-OXIDANTS  
(PLEASE LIST)  
 
PRESCRIBED DRUG USE  
(PLEASE LIST)  
 
RECREATIONAL DRUG USE Y/N   
  
IF YES PLEASE LIST  
11 MEDICAL 
 
  CANCER  
Inflammatory disease                                      
EXTENT    SITE  HISTOLOGY   SURGERY  
 
CANCER  
Inflammatory disease  
Pre cancerous state  
OTHER MEDICAL CONDITIONS  
(PLEASE LIST)  
Family history of cancer and  
Inflammatory disease  
Chemotherapy or radiotherapy 
 
 
CURRENT SMOKER  Y/N PAST SMOKER Y/N HOW MANY/MUCH PER DAY? 
CIGARETTES   CIGARS   PIPE   
ALCOHOL Y/N               UNITS PER WEEK  
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Appendix 5 – Participant information sheet  
 
 School of Life Sciences 
  
 
Participant Information Sheet for patients   
 
Study title: Genetic and environmental effects in lymphocytes from different 
cancerous, precancerous and inflammatory conditions using various genetic 
endpoints 
 
Reviewed by Leeds East Research Ethics Committee (REC) 
 (REC reference number: 12/YH/0464  ) 
Invitation to the research study 
We would like to invite you to take part in a research study. Before you decide you need 
to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if 
you wish to and you will be allowed around 24hours to consider this.  
(Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study).  
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
Part 1 
In this study white blood cells will be treated in a test tube with chemical solutions or 
particles or UV radiation to determine if patients with cancerous and inflammatory 
diseases are more at risk after exposure. A blood sample of around 2 teaspoons (5-7 ml) 
will be taken. Samples will be stored only for the duration of the study and used for 
studies of a similar nature or to check original responses. This is for various research 
programmes involving post doctoral fellows and PhDs. 
 
 Why have I been invited? 
 You have been invited because you have a disease state and we should like to 
determine if these chemicals or UV irradiation could be more harmful to people with a 
disease state than those without such a disease. 
 
 Do I have to take part?  
It is up to you to decide.  We shall outline the study and go through this information 
sheet, which we shall then give to you.  We shall ask you to sign a consent form to show 
you have agreed to take part.  You are free to withdraw at any time, without giving a 
reason.  
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Part 2 
What will happen to me if I take part? 
Only a single blood sample will be taken for this research study. A brief questionnaire 
will need to be completed by the researchers. 
 
Each individual will be given a coded study number so that your clinical data can be 
linked in an anonymous way with the research results. 
 
The data obtained will only be available to the research team and will not be returned  
to you. Responses will be compared only on a group basis i.e. collective responses from 
patients with diseases compared to collective responses from people without diseases. 
Results could be published in the form of scientific papers. The work will benefit the 
medical and scientific community at large, but will not be of direct benefit to you as an 
individual.  If, however, you would like more information, the Consultant and research 
team will be  
 prepared to talk to you individually about study results. 
 
People who cannot take part in the study 
People who are not well enough to take part will be excluded.  
 
If you have any further questions, you could contact the research team: 
Mr Salhab, Bradford Teaching Hospitals NHS Foundation Trust   
St Lukes Hospital, BD5 0NA .  
Telephone: 01274 36 5063 
 
Professor Diana Anderson, Established Chair in Biomedical Sciences, BSc, MSc, PhD, 
DipEd, FSB, FATS, FRCPath, FIFST, FBTS, FHEA, University of Bradford, 
Richmond Road, Bradford, BD7 1DP and Honorary Research Consultant to Bradford 
NHS Trust.  
e-mail: d.anderson1@bradford.ac.uk 
 
Dr Mojgan Najafzadeh MD, PhD Post Doctoral Fellow. Division of Medical Sciences, 
University of Bradford, Richmond Road, Bradford, BD7 1DP 
and Honorary Research Consultant to Bradford NHS Trust. 
 
 
